SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES
FIELD OF THE INVENTION
The present invention relates to substituted imidazo[4,5-c]quinoline derivatives,
processes for their preparation, pharmaceutical compositions comprising compounds of the
present invention and their use in the treatment of diseases or disorders mediated by one or
more kinases, particularly proliferative diseases or disorders such as cancer. These
compounds can also be used in the treatment of inflammatory diseases or disorders and
angiogenesis related diseases or disorders.
BACKGROUND OF THE INVENTION
Cancer can be defined as an abnormal growth of tissues characterized by a loss of
cellular differentiation. It is caused due to a deregulation of the signaling pathways involved
in cell survival, cell proliferation and cell death.
Angiogenesis is the process of forming new blood vessels and is critical in many
normal and abnormal physiological states. Angiogenesis is normally observed in wound
healing, fetal and embryonic development and formation of corpus luteum, endometrium and
placenta. However, angiogenesis is also the fundamental step in the transition of tumors from
a dormant state to a malignant state. In diseases like cancer, the body loses the ability to
maintain balanced angiogenesis. New blood vessels feed diseased tissues, destroying normal
tissues and sometimes are involved in tumor metastasis. Hence anti-angiogenic agents are a
very promising class of drugs to block or slow the cancer growth.
Vascular Endothelial Growth Factor (VEGF), a signal protein, stimulates the growth
of new blood vessels. It is involved in both vasculogenesis (the de novo formation of the
embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre
existing vasculature). Anti-VEGF therapies are important in the treatment of age-related
macular degeneration and in certain cancers such as breast cancer, oesophageal cancer,
melanoma, colorectal cancer and tumors of central nervous system.
Protein kinases play important roles in regulating most cellular functions such as
proliferation, cell cycle, cell metabolism, survival, apoptosis, DNA damage repair, cell
motility and response to the microenvironment. Protein kinases can be divided into broad
groups based upon the identity of the amino acid(s) that they target (serine/threonine,
tyrosine, lysine, and histidine). There are also dual-specific protein kinases that target both
tyrosine and serine/threonine, such as Mitogen- Activated Protein Kinases (MAPKs). MAPKs
are commonly activated in cancer cells and are known to contribute to tumorigenesis. The
protein tyrosine kinases (PTKS) comprise a large family of kinases that regulate cell to cell
signals involved in growth, differentiation, adhesion, motility, and death. Members of the
tyrosine kinase include, but are not limited to, Muscle- Specific Receptor Tyrosine Kinase
(MuSK), Janus kinase 2 (JAK2) and Reactive Oxygen Species (ROS). The JAKs are integral
in signaling from extracellular cytokines, including the interleukins, interferons, as well as
numerous hormones. The importance of these kinases in cellular survival is made evident by
the fact that the loss of JAKs is often accompanied by immunodeficiency and non-viability in
animal models.
The family of serine/threonine kinases includes, but is not limited to, DNAdependent
protein kinase (DNA-PK), activin receptor- like kinase 1 (ALK1), activin receptor
like kinase 1 (ALK2), CDC-like kinase 1 (CLK1), CDC-like kinase 4 (CLK4) and receptorinteracting
serine/threonine-protein kinase 2 (RIPK2). The DNA-PK is a nuclear
serine/threonine protein kinase that is activated upon association with DNA. DNA-PK has
been shown to be a crucial component of both the DNA double-strand break (DSB) repair
machinery and the V(D)J recombination apparatus. DNA-PK is required for the non
homologous end joining (NHEJ) pathway of DNA repair, which rejoins double-strand breaks.
Hence DNA-PK finds use in the treatment of cancers. Aberrant activity of ALK (Activin
Like Kinase) is involved in the development of brain tumors and over expression of ALK has
been reported in neuroblastomas and several cell lines derived from neural tissue. ALK
mediated signaling could play a role in the development and/or progression of a number of
common solid tumors (J. Cell. Physiol., 2004, 199(3), 330-58).
ALK- 1 is a type I cell surface receptor for transforming growth factor beta receptor
type I (TGF-bI) . Mutations in ALK-1 are associated with heredity hemorrhagic telangiectesia
(HHT), suggesting a critical role for ALK- 1 in the control of blood vessel development or
repair (J. Med. Genet., 2003, 40, 494-502). Also, in-vivo experiments on ALK-1 knockout
mice provide the evidence of ALK-1 involvement in angiogenesis (Proc. Natl. Acad. Sci,
2000, 97, 2626-2631).
Phosphatidylinositol-3 -kinases or phosphoinositol-3 -kinase (PI3 -kinases or PI3Ks),
are a family of lipid kinases that are capable of phosphorylating the 3 position hydroxyl
group of the inositol ring of phosphatidylinositol. The PI3K family is composed of Class I, II
and III. The classification is based on primary structure, regulation and in vitro lipid substrate
specificity. Class III PI3K enzymes phosphorylate PI (phosphaotidylinositol) alone while,
Class II PI3K enzymes phosphorylate both PI and PI 4-phosphate [PI(4)P]. Class I PI3K
enzymes phosphorylate PI, PI(4)P and PI 4,5-biphosphate [PI(4, 5)P2] . Class I PI3Ks are
further divided into two groups, class la and class lb, in terms of their activation mechanism.
Class la PI3Ks include PI3K p i 10a, p i 10b and p i 10d subtypes and are generally activated in
response to growth factor-stimulation of receptor tyrosine kinases.
PI3K mediated signaling pathway plays a very important role in cancer cell survival,
cell proliferation, angiogenesis and metastasis. Activation of PI3K results in a disturbance of
control of cell growth and survival, and hence this pathway is an attractive target for the
development of novel anticancer agents (Nat. Rev. Drug Discov., 2005, 4, 988-1004).
Activation of PI3K results in the recruitment and activation of protein kinase B (AKT) onto
the membrane, which gets phosphorylated at Serine 473 (Ser-473).
AKT is known to positively regulate cell growth (accumulation of cell mass) by
activating the mTOR serine threonine kinase. Mammalian target of rapamycin (mTOR)
serves as a molecular sensor that regulates protein synthesis on the basis of nutrients. mTOR
regulates biogenesis by phosphorylating and activating p70S6 kinase (S6K1), which in turn
enhances translation of mRNAs that have polypyrimidine tracts. The phosphorylation status
of S6K1 is a bonafide read-out of mTOR function. Most tumors have an aberrant PI3K
pathway (Nat. Rev. Drug Discov., 2005, 4, 988-1004). Since mTOR lies immediately
downstream of PI3K, these tumors also have hyperactive mTOR function. Thus, most of the
cancer types will potentially benefit from molecules that target PI3K and mTOR pathways.
Inhibition of PI3K-Akt pathway suppresses coagulation and inflammation
(Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24,1963). Hence the compounds
that are PI3K and/or mTOR inhibitors, find use in the treatment of cancers, autoimmune and
inflammatory diseases and disorders.
Several proinflammatory cytokines, especially TNF-a (Tumor Necrosis Factor-a) and
interleukins (IL-1 b, IL-6, IL-8) play an important role in the inflammatory process. An
increase in TNF-a synthesis/release is a common phenomenon during the inflammatory
process. Inflammation is an inherent part of various disease states like rheumatoid arthritis,
Crohn's disease, ulcerative colitis, septic shock syndrome, atherosclerosis, among other
clinical conditions.
TNF-a has been implicated as a mediator in several diseases such as inflammatory
bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis,
osteoarthritis, refractory rheumatoid arthritis, chronic non- rheumatoid arthritis,
osteoporosis/bone resorption, Crohn's disease, allergic asthma, septic shock, endotoxic
shock, atherosclerosis, ischemia-reperfusion injury, multiple sclerosis, sepsis, chronic
recurrent uveitis, hepatitis C virus infection, malaria, ulcerative colitis and the like. Much
research has been conducted to study the effect of TNF-a and anti-TNF-a therapies. Studies
in the area of cancer have shown that with TNF-a therapy it is important to balance the
cytotoxicity and systemic toxicity of the potential drug candidates.
GDC-0941 (Piramed Ltd. and Genentech Inc.) is a PI3K inhibitor and is in phase I
clinical trials. BEZ-235 and BGT-226 (Novartis AG), both in phase I/II clinical trials, inhibit
all isoforms of PI3K and also inhibit the kinase activity of mTOR. XL-765 (Exelixis Inc.) is
also a dual inhibitor of mTOR and PI3K. The compound is in phase I clinical trials as an oral
treatment for solid tumors.
PCT publications WO2006/122806 and WO20101 39747 describe imidazoquinoline
compounds as lipid and/or protein kinase inhibitors for the treatment of lipid and/or protein
kinase dependent disease.
SUMMARY OF THE INVENTION
According to one aspect of the present invention there are provided compounds of
formula (I),
(I)
or stereoisomers, tautomers, polymorphs, prodrugs, N-oxides, pharmaceutically acceptable
salts or solvates thereof.
According to another aspect of the present invention there are provided processes for
preparing compounds of formula (I).
According to another aspect of the present invention there are provided novel
intermediates useful for preparing compounds of formula (I).
According to another aspect of the present invention there is provided a method for
inhibiting activity of a kinase selected from PI3K, mTOR, ALK-1 or ALK-2 comprising
contacting the kinase with an effective amount of a compound of formula (I).
According to another aspect of the present invention there is provided a method for
the treatment of proliferative diseases or disorders in a subject, comprising administering to
the subject a therapeutically effective amount of a compound of formula (I) or stereoisomers,
tautomers, N-oxides, pharmaceutically acceptable salts or solvates thereof.
According to another aspect of the present invention there is provided a method for
the treatment of proliferative diseases or disorders mediated by one or more kinases selected
from PI3K, mTOR, ALK-1 or ALK-2 in a subject, comprising administering to the subject in
need thereof a therapeutically effective amount of a compound of formula (I) or a
stereoisomer, a tautomer, a polymorph, a prodrug, an N-oxide, a pharmaceutically acceptable
salt or a solvate thereof. An example of such proliferative diseases or disorders includes, but
is not limited to, cancer.
According to another aspect of the present invention there is provided a method for
inhibiting vascular endothelial growth factor (VEGF), comprising contacting VEGF with an
effective amount of a compound of formula (I).
According to another aspect of the present invention there is provided a method for
the treatment of angiogenesis related diseases or disorders in a subject, comprising
administering to the subject a therapeutically effective amount of a compound of formula (I)
or a stereoisomer or a tautomer, or an N-oxide or a pharmaceutically acceptable salt or a
solvate thereof.
According to another aspect of the present invention, there is provided a method for
the treatment of diseases or disorders mediated by VEGF in a subject, comprising
administering to the subject a therapeutically effective amount of a compound of formula (I)
or a stereoisomer, a tautomer, a polymorph, a prodrug, an N-oxide, a pharmaceutically
acceptable salt and a solvate thereof.
According to another aspect of the present invention there is provided a method for
the treatment of angiogenesis related diseases or disorders mediated by PI3K, mTOR, ALK-
1, ALK-2 or VEGF in a subject, comprising administering to the subject a therapeutically
effective amount of a compound of formula (I) or a stereoisomer, a tautomer, a polymorph, a
prodrug, an N-oxide, a pharmaceutically acceptable salt and a solvate thereof.
According to another aspect of the present invention there is provided a method for
inhibiting tumor necrosis factor-a (TNF- a) or interleukin-6 (IL-6), comprising contacting
TNF- a or IL-6 with an effective amount of a compound of formula (I) .
According to another aspect of the present invention there is provided a method for
the treatment of inflammatory diseases or disorders in a subject, comprising administering to
the subject a therapeutically effective amount of a compound of formula (I) or a stereoisomer
or a tautomer, or an N-oxide or a pharmaceutically acceptable salt or a solvate thereof.
According to another aspect of the present invention, there is provided a method for
the treatment of diseases or disorders mediated by TNF-a or IL-6 in a subject, comprising
administering to the subject a therapeutically effective amount of a compound of formula (I)
or a stereoisomer, a tautomer, a polymorph, a prodrug, an N-oxide, a pharmaceutically
acceptable salt and a solvate thereof.
According to yet another aspect of the present invention there is provided a compound
of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of
proliferative diseases or disorders mediated by PI3K, mTOR, ALK-1 or ALK-2. An example
of such proliferative diseases or disorders includes, but is not limited to, cancer.
According to yet another aspect of the present invention there is provided a compound
of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of
angiogenesis related diseases or disorders mediated by PI3K, mTOR, ALK-1, ALK-2 or
VEGF.
According to yet another aspect of the present invention there is provided a compound
of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of
diseases mediated by TNF-a or IL-6.
According to yet another aspect of the present invention there is provided a compound
of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of
inflammatory diseases or disorders.
According to another aspect of the present invention there is provided a
pharmaceutical composition, comprising a compound of formula (I) or a pharmaceutically
acceptable salt thereof in association with a pharmaceutically acceptable carrier, adjuvant, or
vehicle.
These and other objectives and advantages of the present invention will be apparent to
those skilled in the art from the following description.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGS. 1A-1E are reproductions of Western blots showing the effect of certain
compounds of the invention on the key proteins of the PI3K/mTOR pathway.
FIG. 2 is a scan of endothelial cells showing the effect of the Example 3a on VEGF
(40 ng/mL) induced tube formation.
FIG. 3A is a graph of Tumor Weight versus Days post tumor transplantation for mice
with human PC3 xenograft tumors administered with the compound of Example 19, or with
the compound of Example 3a at the indicated dose and route.
FIG. 3B is a graph of Tumor Weight versus Days post tumor transplantation for mice
with human PANC-1 xenograft tumors administered with the compound of Example 3a.
FIG. 4A is a graph of the change in paw thickness versus day of study for arthritic
DBA/IJ mice treated with the compound of Example 19, Enbrel and vehicle (0.5% CMC).
FIG. 4B is a graph of the change in articular index versus day of study for arthritic
DBA/IJ mice treated with the compound of Example 19, Enbrel and vehicle (0.5% CMC).
DETAILED DESCRIPTION OF THE INVENTION
DEFINITIONS
Listed below are definitions, which apply to the terms as they are used throughout the
specification and the appended claims (unless they are otherwise limited in specific
instances), either individually or as part of a larger group. It will be understood that
"substitution" or "substituted by" or "substituted with" includes the implicit proviso that such
substitution is in accordance with the permitted valence of the substituted atom and the
substituent, as well as represents a stable compound, which does not readily undergo
transformation such as by rearrangement, cyclization, elimination, etc.
The term "halo" or "halogen" as used herein refers to an atom selected from F, CI, Br
and I .
The term "alkyl" whether used alone or as part of a substituent group, refers to the
radical of saturated aliphatic groups, including straight or branched-chain containing from 1
to 12 carbon atoms, for example, 1 to 6 carbons atoms, such as 1 to 4 carbon atoms.
Examples of alkyl groups include but are not limited to methyl, ethyl, propyl, butyl,
isopropyl, isobutyl, 1-methylbutyl, sec-butyl, tert-butyl, pentyl, -pentyl, «-hexyl, n-decyl,
tetradecyl and the like.
The term "alkenyl" refers to an unsaturated, branched or straight chain alkyl group
having from 2 to 10 carbon atoms, suitably 2 to 4 carbon atoms and at least one carboncarbon
double bond (two adjacent sp2 carbon atoms). Depending on the placement of double
bond and substituents if any, the geometry of the double bond may be entgegen (E), or
zusammen (Z), cis or trans. Examples of alkenyl include but are not limited to ethenyl
(vinyl), 1-propenyl (allyl), 2-propenyl and the like.
As used herein the term "haloalkyl", means alkyl radical which is substituted by one
or more halogen atoms (F, CI, Br or I). An example of a haloalkyl is a halo (Ci-C4)alkyl
including, but not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl,
2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2,2,2-trifluoro- 1,1-dimethylethyl, 2,2,2-trichloroethyl,
3-fluoropropyl, 4-fluorobutyl, chloromethyl, trichloromethyl, iodomethyl, bromomethyl and
4,4,4-trifluoro-3 -methylbutyl groups. Preferred halo(Ci-C4)alkyl groups are fluoromethyl,
difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl and
2,2,2-trifluoro- 1,1-dimethylethyl groups.
The term "aryl" as used herein refers to a monocyclic or polycyclic hydrocarbon
group having 6 to 14 ring carbon atoms, preferably up to 10 ring carbon atoms, more
preferably up to 6 ring carbon atoms in which at least one carbocyclic ring is present that has
a conjugated p electron system. Accordingly, the term "aryl" refers to C6-C14 aryl. Examples
of aryl include but are not limited to phenyl, naphthyl, tetrahydronaphthyl and the like. Aryl
residues can be bonded via any desired position, and in substituted aryl residues, the
substituents can be located in any desired position.
In some embodiments, a C6-C14 aryl is selected from the group consisting of phenyl,
indenyl, naphthyl, azulenyl, heptalenyl, biphenyl, indacenyl, acenaphthylenyl, fluorenyl, 1Hphenalenyl,
phenanthrenyl or anthracenyl. In some embodiments, -C6 -C14 aryl is selected
from the group consisting of phenyl, naphthyl, anthracenyl and lH-phenalenyl.
The term "heteroaryl" as used herein refers to an aromatic heterocyclic ring system
containing 5 to 20 ring atoms, suitably 5 to 10 ring atoms, which may be a monocyclic or
polycyclic, fused together or linked covalently. The rings may contain from 1 to 4
heteroatoms selected from N, O and S, wherein the N or S atom is optionally oxidized, or the
N atom is optionally quaternized. Any suitable ring position of the heteroaryl moiety may be
covalently linked to the defined chemical structure. Examples of heteroaryl include, but are
not limited to, furanyl, thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl,
thiazolyl, isothiazolyl, IH-tetrazolyl, oxadiazolyl, triazolyl, pyridyl, pyrimidinyl, pyrazinyl,
pyridazinyl, benzoxazolyl, benzothiazolyl, benzofuranyl, benzothienyl, phthalazinyl,
dibenzofuranyl, benzimidazolyl, indolyl, isoindolyl, indazolyl, quinolinyl, isoquinolinyl,
quinazolinyl, quinoxalinyl, purinyl, indolizinyl, benzoisothiazolyl, benzoxazolyl,
pyrrolopyridyl, furopyridinyl, benzothiadiazolyl, benzooxadiazolyl, benzotriazolyl,
benzodiazolyl, dibenzothienyl and the like.
The foregoing heteroaryl groups may be C-attached or N-attached (where such an
attachment is possible). For instance, a group derived from pyrrole may be pyrrol- 1-yl (
attached) or pyrrol-3-yl (C-attached).
The term "heterocyclyl" or "heterocycle" as used herein refers to a saturated or
partially unsaturated monocyclic or polycyclic ring system containing 5 to 20 ring atoms of
which 1, 2, 3 or 4 are identical or different heteroatoms selected from N, O and S. The
"heterocyclyl" or "heterocycle" may, for example, have 1 to 2 oxygen atoms and/or 1 to 2
sulfur atoms and/or 1 to 4 nitrogen atoms in the ring. The "heterocyclyl" or "heterocycle"
preferably is a 5- or 6-membered ring. The ring heteroatoms can be present in any position
with respect to each other provided that the resulting "heterocyclyl" or "heterocycle" is
stable. Examples of "heterocyclyl" or "heterocycle" include but are not limited to:
decahydroquinolinyl, oxadiazolidinyl, imidazolidinyl, indolinyl, isobenzofuranyl,
morpholinyl, octahydroisoquinolinyl, oxazolidinyl, piperidinyl, piperazinyl, pyrazolinyl,
pyrazolidinyl, pyrrolidinyl, pyrrolinyl, tetrahydrofuranyl, benzodioxolyl,
tetrahydroisoquinolinyl, and tetrahydroquinolinyl.
The term "alkylheterocyclyl" as used herein refers to a heterocyclyl group bonded
through an alkyl, wherein the terms "alkyl" and "heterocycle" are as defined herein above.
Examples of alkylheterocycle include but are not limited to piperazin- 1-ylmethyl, piperidin-
1-ylmethyl, pyrrolidin-2-ylmethyl, 2-morpholinoethyl and the like.
The term "alkylheteroaryl" as used herein refers to a heteroaryl group bonded through
an alkyl, wherein the terms "alkyl" and "heteroaryl" are as defined herein above. Examples of
alkylheteroaryl include but are not limited to pyrazolylmethyl, pyrazolylethyl, pyridylmethyl,
pyridylethyl, thiazolylmethyl, thiazolylethyl, imidazolylmethyl, imidazolylethyl,
thienylmethyl, thienylethyl, furanylmethyl, furanylethyl, isoxazolylmethyl, isoxazolylethyl,
pyrazinylmethyl and pyrazinylethyl and the like.
The term "compound of the present invention" and "compound of this invention" and
"compounds of formula (I)" includes compounds of formula (I) and stereoisomers, tautomers,
N-oxides, solvates, polymorphs, prodrugs; pharmaceutically acceptable salts or solvates
thereof.
The term "stereoisomer" as used herein refers to all isomers of individual compounds
that differ only in the orientation of their atoms in space. The term stereoisomer includes
mirror image isomers (enantiomers), mixtures of mirror image isomers (racemates, racemic
mixtures), geometric (cis/trans or syn/anti or E/Z) isomers, and isomers of compounds with
more than one chiral center that are not mirror images of one another (diastereoisomers). The
compounds of the present invention may have asymmetric centers and occur as racemates,
racemic mixtures, individual diastereoisomers, or enantiomers, or may exist as geometric
isomers, with all isomeric forms of said compounds being included in the present invention.
The term "tautomer" as used herein refers to the coexistence of two (or more)
compounds that differ from each other only in the position of one (or more) mobile atoms and
in electron distribution, for example, keto-enol and imine-enamine tautomers.
The term "solvate" as used herein refers to a compound formed by the interaction of a
solute (in this invention, a compound of formula (I) or a salt thereof) and a solvent. Such
solvents for the purpose of the invention may not interfere with the biological activity of the
solute. Examples of suitable solvents include, but are not limited to, water, methanol, ethanol
and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent.
Examples of suitable pharmaceutically acceptable solvents include, without limitation, water,
ethanol and acetic acid. Most preferably the solvent used is water. Examples for suitable
solvates are the mono- or dihydrates or alcoholates of the compounds according to the
invention.
The term "pharmaceutically acceptable salts" as used herein refers to inorganic and
organic salts of a compound of the invention. The compounds of the present invention
represented by formula (I), which contain acidic groups, may be converted into salts with
pharmaceutically acceptable bases. Such salts include, for example, alkali metal salts, like
lithium, sodium and potassium salts; alkaline earth metal salts like calcium and magnesium
salts; ammonium salts; [tris(hydroxymethyl)aminomethane], trimethylamine salts and
diethylamine salts; salts with amino acids such as lysine, arginine, guanidine and the like.
The compounds of the present invention represented by formula (I), which contain
one or more basic groups, i.e. groups which can be protonated, can form an addition salt with
an inorganic or organic acid. Examples of suitable acid addition salts include: hydrochlorides,
hydrobromides, hydrofluorides, nitrates, acetates, alginates, ascorbates, aspartates, benzoates,
benzenesulfonates, bisulfates, borates, cinnamates, citrates, ethanesulfonates, fumarates,
glucuronates, glutamates, glycolates, ketoglutarates, lactates, maleates, malonates, mesylates,
oxalates, palmoates, perchlorates, phosphates, picrates, salicylates, succinates, sulfamates,
sulfates, tartrates, tosylates and other acids known to the person skilled in the art.
The term "N-oxide" as used herein in reference to the compounds of formula (I) refers
to the oxide of the nitrogen atom of a nitrogen-containing heteroaryl or heterocycle. N-oxide
can be formed in presence of an oxidizing agent for example peroxide such as m-chloroperbenzoic
acid or hydrogen peroxide.
Various polymorphs of compounds of formula (I), forming part of this invention may
be prepared by crystallization of compounds of formula (I) under different conditions. The
different conditions are, for example, using different commonly used solvents or their
mixtures for crystallization; crystallization at different temperatures; various modes of
cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may
also be obtained by heating or melting the compound followed by gradual or fast cooling.
The presence of polymorphs may be determined by infrared spectroscopy, solid probe
nuclear magnetic resonance (NMR) spectroscopy, differential scanning calorimetry, powder
x-ray diffraction or such other techniques.
The term "prodrug" as used herein refers to a compound that is a drug precursor,
which, following administration into or onto the body, releases the drug in vivo via a
chemical or physiological process, e.g., a prodrug on being brought to physiological pH or
through an enzyme action is converted to the desired drug form. Various forms of prodrugs
are known in the art and further information is discussed in Pro-drugs as Novel Delivery
Systems, Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella), Bioreversible Carriers
in Drug Design, Pergamon Press, 1987 (Ed. E. B. Roche, American Pharmaceutical
Association) and Design of Prodrugs, Elsevier 1985, (edited by H. Bundgaard). Exemplary
prodrugs include esters of carboxylic acids such as methyl and ethyl esters, ethers of alcohols
and amides of amines. Pharmaceutically acceptable esters can be converted under
physiological conditions to the carboxylic acid of formula (I).
The present invention also includes within its scope all isotopically labeled forms of
compounds of formula (I), wherein one or more atoms of compounds of formula (I) are
replaced by their respective isotopes. All isotopes of any particular atom or element as
specified are contemplated within the scope of the compounds of the invention. Examples of
isotopes that may be incorporated into the compounds disclosed herein include, but are not
limited to, isotopes of hydrogen such as H and H, carbon such as C, C and 4C, nitrogen
such as N and N, oxygen such as 0 , 0 and 80 , chlorine such as C1, fluorine such as
8F and sulphur such as S. Substitution with heavier isotopes, for example, replacing one or
more key carbon-hydrogen bonds with carbon-deuterium bond may show certain therapeutic
advantages, resulting from longer metabolism cycles, (e.g., increased in-vivo half life or
reduced dosage requirements), improved safety or greater effectiveness and hence may be
preferred in certain circumstances.
EMBODIMENTS
The present invention provides compounds of formula (I),
formula (I)
or stereoisomers, tautomers, polymorphs, prodrugs, N-oxides, pharmaceutically acceptable
salts or solvates thereof, wherein,
R is selected from alkylheterocyclyl, alkylheteroaryl or heteroaryl, wherein each of
heterocyclyl and heteroaryl is optionally substituted with one or more groups selected from
R
R2 is -C1-C4 alkyl, optionally substituted with one or more groups independently
selected from
-CN or -C2-C4 alkenyl;
R3 is selected from heteroaryl or -C6 -C14 aryl, wherein each of aryl and heteroaryl is
optionally substituted with one or more groups selected from R ;
R at each occurrence is independently selected from halogen, -CN, -ORx, -NRxRy, -
NRxCORy, -COORx, -CONRxR , halo-Ci-C 4 alkyl, -C1-C4 alkyl, heterocyclyl or heteroaryl,
wherein each of alkyl, heterocyclyl, and heteroaryl is optionally substituted with one or more
groups independently selected from -CN or -C1-C4 alkyl;
R31 at each occurrence is independently selected from halogen, -ORx, -CN, -NR xRy, -
NRxCORy, -COORx, -CONR xRy, halo-Ci-C 4 alkyl or -C1-C4 alkyl;
wherein Rx and Ry at each occurrence are independently selected from hydrogen or -
C1-C4 alkyl.
One embodiment of the present invention is a compound of formula (I), wherein R is
heteroaryl, wherein heteroaryl is optionally substituted with one or more groups selected
from R .
Another embodiment is a compound of formula (I), wherein R is a heteroaryl,
wherein the heteroaryl is optionally substituted with one or more groups independently
selected from halogen, -CN, -ORx, -NRxRy, halo-Ci-C4 alkyl, -C1-C4 alkyl, heterocyclyl or
heteroaryl, wherein each of -C1-C4 alkyl, heterocyclyl or heteroaryl is optionally substituted
with one or more groups independently selected from -CN or -C1-C4 alkyl and Rx and Ry at
each occurrence are independently selected from hydrogen or -C1-C4 alkyl.
Another embodiment is a compound of formula (I), wherein R is a heteroaryl
selected from pyridyl, pyrimidinyl or quinolinyl, wherein the pyridyl, pyrimidinyl and
quinolinyl are optionally substituted with one or more groups selected from R .
Another embodiment is a compound of formula (I), wherein R is a heteroaryl
selected from pyridyl, pyrimidinyl or quinolinyl, wherein the pyridyl, pyrimidinyl and
quinolinyl are optionally substituted with one or more groups independently selected from
halogen, -CN, -OR x, -NR xRy, halo-Ci-C4 alkyl, -C1-C4 alkyl, heterocyclyl or heteroaryl,
wherein each of the -C1-C4 alkyl, heterocyclyl and heteroaryl is optionally substituted with
one or more groups independently selected from -CN or -C1-C4 alkyl and Rx and Ry at each
occurrence are independently selected from hydrogen or -C1-C4 alkyl.
Another embodiment is a compound of formula (I), wherein R is pyridyl, optionally
substituted with one or more groups selected from R .
Another embodiment is a compound of formula (I), wherein R is pyridyl, optionally
substituted with one or more groups independently selected from halogen, -CN, -OR x, -
NRxRy, halo-Ci-C4 alkyl, -C1-C4 alkyl, heterocyclyl or heteroaryl, wherein each of -C1-C4
alkyl, heterocyclyl and heteroaryl is optionally substituted with one or more groups
independently selected from -CN or -C1-C4 alkyl and Rx and Ry at each occurrence are
independently selected from hydrogen or -C1-C4 alkyl.
Another embodiment is a compound of formula (I), wherein R is 3-pyridyl,
optionally substituted with one or more groups selected from R .
Another embodiment is a compound of formula (I), wherein R is represented by the
structural formula , wherein each of R and R 2 is independently selected
from hydrogen, halogen, -CN, -OR x, -NR xRy, halo-Ci-C4 alkyl, -C1-C4 alkyl, heterocyclyl or
heteroaryl, wherein the -C1-C4 alkyl is optionally substituted with -CN and the heterocyclyl
and heteroaryl are optionally substituted with -C1-C4 alkyl; Rx and Ry at each occurrence are
independently selected from hydrogen or -C1-C4 alkyl and the symbol ^indicates the point of
attachment to the rest of the molecule.
ompound of formula (I), wherein R is represented by the
, wherein each of R and R 2 is independently selected
from hydrogen, halogen, -CN, -OCH3, -N(CI¼) 2, -CF , -C1-C4 alkyl, morpholinyl,
piperazinyl or pyridyl, wherein the -C1-C4 alkyl is optionally substituted with -CN, and the
piperazinyl is optionally substituted with -C1-C4 alkyl and the symbol ^indicates the point of
attachment to the rest of the molecule.
Another embodiment is a compound of formula (I), wherein R is represented by the
structural formula , wherein R i is selected from -CI, -CN, -OCH 3, -OC2H 5,
-N(Ci¼)2, -CF 3, -C(CH )2CN, morpholinyl or piperazinylmethyl; R 2 is selected from
hydrogen, CI, CH3 or pyridyl and the symbol indicates the point of attachment to the rest of
the molecule.
Another embodiment is a compound of formula (I), wherein R is quinolinyl,
optionally substituted with one or more groups selected from R .
Another embodiment is a compound of formula (I), wherein R is quinolinyl.
Another embodiment is a compound of formula (I), wherein R is pyrimidinyl,
optionally substituted with one or more groups selected from R .
Another embodiment is a compound of formula (I), wherein R is pyrimidinyl,
optionally substituted with halo-Ci-C4-alkyl.
Another embodiment is a compound of formula (I), wherein R is alkylheterocyclyl,
wherein the heterocyclyl moiety is optionally substituted with one or more groups selected
from R .
Another embodiment is a compound of formula (I), wherein R is 2-morpholinoethyl.
Another embodiment is a compound of formula (I), wherein R is -C1-C4 alkyl,
optionally substituted with -CN.
Another embodiment is a compound of formula (I), wherein R is halo-Ci-C4 alkyl.
Another embodiment is a compound of formula (I), wherein R is -ORx, wherein Rx
is selected from hydrogen or -C1-C4 alkyl.
Another embodiment is a compound of formula (I), wherein R is heterocyclyl,
optionally substituted with -C1-C4 alkyl.
Another embodiment is a compound of formula (I), wherein R is heteroaryl.
Another embodiment is a compound of formula (I), wherein R is pyridyl.
Another embodiment is a compound of formula (I), wherein R2 is methyl optionally
substituted with one or more groups independently selected from -CN or -C2-C4 alkenyl.
Another embodiment is a compound of formula (I), wherein R2 is methyl.
Another embodiment is a compound of formula (I), wherein R2 is cyanomethyl.
Another embodiment is a compound of formula (I), wherein R2 is allyl.
Another embodiment is a compound of formula (I), wherein R is heteroaryl
optionally substituted with one or more groups selected from R .
Another embodiment is a compound of formula (I), wherein R is heteroaryl
optionally substituted with one or more groups independently selected from halogen, -ORx, -
NRxRy, -Ci-C4-alkyl or halo-Ci-C4-alkyl, wherein Rx and Ry at each occurrence are
independently selected from hydrogen or -C1-C4 alkyl.
Another embodiment is a compound of formula (I), wherein R 3 is selected from
pyridyl or quinolinyl optionally substituted with one or more groups selected from R .
Another embodiment is a compound of formula (I), wherein R 3 is selected from
pyridyl or quinolinyl optionally substituted with one or more groups independently selected
from halogen, -ORx, NRxRy, -Ci-C4-alkyl or halo-Ci-C4-alkyl, wherein Rx and Ry at each
occurrence are independently selected from hydrogen and -C1-C4 alkyl.
Another embodiment is a compound of formula (I), wherein R 3 is pyridyl optionally
substituted with one or more groups selected from R31 .
Another embodiment is a compound of formula (I), wherein R 3 is pyridyl optionally
substituted with one or more groups independently selected from halogen, -ORx, NRxRy, -Ci-
C 4-alkyl or halo-Ci-C4-alkyl, wherein Rx and Ry at each occurrence are independently
selected from hydrogen or -C1-C4 alkyl.
Another embodiment is a compound of formula (I), wherein R 3 is 3-pyridyl optionally
substituted with one or more groups selected from R31 .
Another embodiment is a compound of formula (I), wherein R 3 is represented by the
structural formula , wherein each of R31 1, R312 and R313 is independently
selected from hydrogen, halogen, -ORx, -NRxRy, -Ci-C4-alkyl or halo-Ci-C4-alkyl, wherein
Rx and Ry at each occurrence are independently selected from hydrogen or -C1-C4 alkyl.
Another embodiment is a compound of formula (I), wherein R 3 is represented by the
structural formula , wherein each of R31 1, R312 and R313 is independently
selected from hydrogen, halogen, -O-C1-C4 alkyl, -NH2, -NH-Ci-C 4-alkyl, -N(Ci-C 4-alkyl)2
or methyl, wherein methyl is optionally substituted with one to three halogen atoms and the
symbol indicates the point of attachment to the rest of the molecule.
Another embodiment is a compound of formula (I), wherein R is represented by the
structural formula , wherein each of R31 1, R312 and R313 is independently
selected from hydrogen, F, -OCH3, -NH2, -NH-CH 3, -N(CH )2 or -CF and the symbol^
indicates the point of attachment to the rest of the molecule.
formula (I), wherein R 3 is represented by the
s R31 1 is -NH2; R312 and R313 are independently
selected from hydrogen, halogen, -O-C1-C4 alkyl, -NH2, -NH-Ci-C 4-alkyl, -N(Ci-C 4-alkyl) 2
or methyl, wherein methyl is optionally substituted with one to three halogen atoms and the
symbol indicates the point of attachment to the rest of the molecule.
Another embodiment is a compound of formula (I), wherein R 3 is represented by the
structural formula , wherein R is -CF3 and R31 1 and R312 are
independently selected from hydrogen, halogen, -O-C1-C4 alkyl, -NH2, -NH-Ci-C 4-alkyl, -
N(Ci-C 4-alkyl)2 or methyl, wherein methyl is optionally substituted with one to three halogen
atoms and the symbol indicates the point of attachment to the rest of the molecule.
Another embodiment is a compound of formula (I), wherein R 3 is represented by the
structural formula , wherein R is -NH2 and R313 is -CF3 and R312 is
selected from hydrogen, halogen, -O-C1-C4 alkyl, -NH2, -NH-Ci-C 4-alkyl, -N(Ci-C 4-alkyl) 2
or methyl; wherein methyl is optionally substituted with one to three halogen atoms and the
symbol indicates the point of attachment to the rest of the molecule.
Another embodiment is a compound of formula (I), wherein R 3 is represented by the
structural formula wherein R is -NH2, R313 is -CF3 and R312 is hydrogen
and the symbol indicates the point of attachment to the rest of the molecule.
Another embodiment is a compound of formula (I), wherein R is quinolinyl
optionally substituted with -ORx, wherein Rx is selected from hydrogen or -C1-C4 alkyl.
Another embodiment is a compound of formula (I), wherein R is quinolinyl.
Another embodiment is a compound of formula (I), wherein R is quinolinyl
substituted with -OH.
Another embodiment is a compound of formula (I), wherein R 3 is pyrimidinyl
optionally substituted with -ORx, wherein Rx is selected from hydrogen or -C1-C4 alkyl.
Another embodiment is a compound of formula (I), wherein R 3 is pyrimidinyl.
Another embodiment is a compound of formula (I), wherein R 3 is pyrimidinyl
optionally substituted with -OCH 3.
Another embodiment is a compound of formula (I), wherein R 3 is -C6 -C14 aryl
optionally substituted with one or more groups selected from R .
Another embodiment is a compound of formula (I), wherein R 3 is -C6 -C14 aryl
optionally substituted with one or more groups independently selected from halogen, -ORx or
methyl, wherein methyl is optionally substituted with one to three halogen atoms, wherein Rx
is selected from hydrogen or -C1-C4 alkyl.
Another embodiment is a compound of formula (I), wherein R 3 is phenyl optionally
substituted with one or more groups independently selected from halogen, -ORx or methyl,
wherein methyl is optionally substituted with one to three halogen atoms, wherein Rx is
selected from hydrogen and -C1-C4 alkyl.
Another embodiment is a compound of formula (I), wherein R 3 is phenyl optionally
substituted with one or more groups independently selected from F, -OCH 3 or CF3.
Another embodiment is a compound of formula (I), wherein R is heteroaryl
optionally substituted with one or more groups selected from R R2 is -C1-C4 alkyl
optionally substituted with one of more groups independently selected from -CN or -C2-C4
alkenyl; and R 3 is heteroaryl or -C6 -C14 aryl optionally substituted with one or more groups
selected from R .
Another embodiment is a compound of formula (I), wherein R is heteroaryl
optionally substituted with one or more groups selected from R ; R2 is -C1-C4 alkyl
optionally substituted with one or more groups independently selected from -CN or -C2-C4
alkenyl; and R3 is heteroaryl optionally substituted with one or more groups selected from
R3 1.
Another embodiment is a compound of formula (I), wherein R is heteroaryl
optionally substituted with one or more groups selected from halogen, -CN, -OR x, -NR xRy,
halo-Ci-C4 alkyl, -C1-C4 alkyl, heterocyclyl or heteroaryl, wherein each of -C1-C4 alkyl and
heterocyclyl is optionally substituted with one or more groups independently selected from -
CN or -C1-C4 alkyl; R2 is -C1-C4 alkyl optionally substituted with one or more groups
independently selected from -CN or -C2-C4 alkenyl; and R3 is heteroaryl optionally
substituted with one or more groups independently selected from halogen, -OR x, -NR xRy or
halo-Ci-C4 alkyl, wherein Rx and Ry at each occurrence are independently selected from
hydrogen or -C1-C4 alkyl.
Another embodiment is a compound of formula (I), wherein R is heteroaryl
optionally substituted with one or more groups independently selected from CI, -CN, -OCH 3,
-OC 2H , -N(CH 3)2, -CF 3, -CH 3, -C(CH )2CN, morpholinyl, piperazinyl or pyridyl; R2 is
methyl optionally substituted with -CN; and R3 is heteroaryl optionally substituted with one
or more groups independently selected from F, -OH, -OCH3, -NH 2, -NHCH3, -N (ϋ )2 or -
CF .
Another embodiment is a compound of formula (I), wherein R is selected from
pyridyl, pyrimidinyl or quinolinyl, wherein pyridyl, pyrimidinyl and quinolinyl are optionally
substituted with one or more groups selected from R ; R2 is methyl optionally substituted
with one or more groups independently selected from -CN or -C2-C4 alkenyl; and R3 is
selected from pyridyl or quinolinyl, wherein pyridyl and quinolinyl are optionally substituted
with one or more groups selected from R .
Another embodiment is a compound of formula (I), wherein R is selected from
pyridyl, pyrimidinyl or quinolinyl, wherein pyridyl, pyrimidinyl and quinolinyl are optionally
substituted with one or more groups independently selected from halogen, -CN, -OR x, -
NRxRy, halo-Ci-C4 alkyl, -C1-C4 alkyl, heterocyclyl or heteroaryl, wherein each of -C1-C4
alkyl, heterocyclyl and heteroaryl is optionally substituted with one or more groups
independently selected from -CN or -C1-C4 alkyl; R2 is allyl or methyl optionally substituted
with -CN; and R3 is selected from pyridyl or quinolinyl; wherein pyridyl and quinolinyl are
optionally substituted with one or more groups independently selected from halogen, -OR x,
NRxRy, -Ci-C4-alkyl or halo-Ci-C4-alkyl, wherein Rx and Ry at each occurrence are
independently selected from hydrogen or -C1-C4 alkyl.
Another embodiment is a compound of formula (I), wherein R is heteroaryl
optionally substituted with one or more groups selected from R ; R2 is allyl or -C1-C4 alkyl,
wherein -C1-C4 alkyl is optionally substituted with -CN; and R 3 is -C6-C14 aryl optionally
substituted with one or more groups selected from R31 .
Another embodiment is a compound of formula (I), wherein the pharmaceutically
acceptable salt of the compound of formula (I) is selected from (a) an inorganic acid addition
salt selected from hydrochloride, sulphate, phosphate or nitrate, and (b) an organic acid
addition salt selected from acetate, maleate, tartarate, citrate, mesylate, tosylate or cinnamate.
Representative compounds, encompassed in accordance with the present invention
include:
2-Methyl-2-(5-(3-methyl-2-oxo-8-(pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-lyl)
pyridin-2-yl)propanenitrile,
2-Methyl-2-(5-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-lyl)
pyridin-2-yl)propanenitrile,
2-(5-(8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lHimidazo[
4,5-c]quinolin-l-yl)pyridin-2-yl)-2-methylpropanenitrile,
2-Methyl-2-(5-(3-methyl-2-oxo-8-(5-(trifluoromethyl)pyridin-3-yl)-2,3-dihydro-lHimidazo[
4,5-c]quinolin-l-yl)pyridin-2-yl) propanenitrile,
2-Methyl-2-(5-(3-methyl-2-oxo-8-(quinolin-6-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-lyl)
pyridin-2-yl) propanenitrile,
2-(5-(8-(Isoquinolin-4-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-lyl)
pyridin-2-yl)-2-methylpropanenitrile,
2-(5-(8-(2-Hydroxyquinolin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-lyl)
pyridin-2-yl)-2-methylpropanenitrile,
2-(5-(8-(6-(Dimethylamino) pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)-2-methylpropanenitrile,
2-Methyl-2-(5-(3-methyl-2-oxo-8-(pyrimidin-5-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-
1-yl)pyridin-2-yl)propanenitrile,
2-(5-(8-(2,6-Difluoropyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin1-
yl)pyridin-2-yl)-2-methylpropanenitrile,
2-(5-(8-(5-Fluoro-2-methoxyphenyl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)-2-methylpropanenitrile,
2-(5-(8-(2-Fluoro-5-(trifluoromethyl) phenyl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)-2-methylpropanenitrile,
2-(5-(8-(2,4-Dimethoxypyrimidin-5-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)-2-methylpropanenitrile,
2-(5-(3-(Cyanomethyl)-2-oxo-8-(pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-lyl)
pyridin-2-yl)-2-methylpropanenitrile,
l-(6-(Dimethylamino)pyridin-3-yl)-3-methy^
2(3H)-one,
2-(5-(8-(6-Amino-5-(nifluoromethyl)pyridin-3-yl)-3-(cyanomethyl)-2-oxo-2,3-dihydro-lHimidazo[
4,5-c]quinolin-l-yl)pyridin-2-yl)-2-methylpropaneninile,
2-(5-(3-(Cyanomethyl)-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-lyl)
pyridin-2-yl)-2-methylpropanenitrile,
2-(5-(3-Allyl-2-oxo-8-(pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-l-yl)pyridin-2-
yl)-2-methylpropanenitrile,
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-l-(6-methoxypyridin-3-yl)-3-methyl-lHimidazo[
4,5-c]quinolin-2(3H)-one,
l-(6-Methoxypyridin-3-yl)-3-methyl-8-(qum^
one,
2-(l-(6-Methoxypyridin-3-yl)-2-oxo-8-(pyridin-3-yl)-lH-imidazo[4,5-c]quinolin-3(2H)-
yl)acetonitrile,
1-(6-Methoxypyridin-3-yl)-3-methyl-8-(5-(trifluoromethyl) pyridin-3-yl)-lH-imidazo[4,5-c]
quinolin-2(3H)-one,
1-(6-Methoxypyridin-3-yl)-3-methyl-8-(pyridin-3-yl)- lH-imidazo[4,5-c] quinolin-2(3H)-one,
2-(l -(6-Methoxypyridin-3-yl)-2-oxo-8-(quinolm
acetonitrile,
8-(6-(Dimethylamino)pyridin-3-yl)-l-(6-methoxypyridin-3-yl)-3-methyl-lH-imidazo[4,5
quinolin-2(3H)-one,
l-(6-Methoxypyridin-3-yl)-3-methyl-8-(6-(methylamino)-5-(trifluoromethyl)pyridin-3-yl)-
lH-imidazo[4,5-c] quinolin-2(3H)-one,
8-(2-Fluoro-5-(trifluoromethyl)phenyl)-l-(6-methoxypyridin-3-yl)-3-methyl-lHimidazo[
4,5-c] quinolin-2(3H)-one,
1-(6-Methoxypyridin-3-yl)-3-methyl-8-(pyridin-4-yl)- lH-imidazo[4,5-c] quinolin-2(3H)-one,
8-(5-Fluoro-2-methoxyphenyl)-l-(6-methoxypyridin-3-yl)-3-methyl-lH-imidazo[4,5-
c]quinolin-2(3H)-one,
8-(6-Amino-5-(trifluoromethyl) pyridin-3-yl)-l-(6-ethoxypyridin-3-yl)-3-methyl-lHimidazo[
4,5-c]quinolin-2(3H)-one,
8-(6-(Dimethylamino) pyridin-3-yl)-l-(6-ethoxypyridin-3-yl)-3-methyl-lH-imidazo [4,5-
c]quinolin-2(3H)-one,
l-(6-Ethoxypyridin-3-yl)-3-methyl-8-(quinolin-3-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-one
8-(2,6-Difluoropyridin-3-yl)-l-(6-ethoxypyridin-3-yl)-3-methyl-lH-imidazo[4,5-c]quinoH^
2(3H)-one,
l-(6-Ethoxypyridin-3-yl)-8-(2-methoxypyrim
2(3H)-one,
1-(6-Ethoxypyridin-3-yl)-3-methyl-8-(quinolin-6-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-on^
2-(l-(6-Methoxy-2-methylpyridin-3-yl)-2-oxo-8-(quinolin-3-yl)-lH-imidazo[4,5-c]quinolin-
3(2H)-yl) acetonitrile,
2-(l-(6-Methoxy-2-methylpyridin-3-yl)-2-oxo-8-(6-(trifluoromethyl)pyridin-3-yl)-lHimidazo[
4,5-c]quinolin-3(2H)-yl) acetonitrile,
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-l-(6-methoxy-2-methylpyridin-3-yl)-3-meth
lH-imidazo[4,5-c]quinolin-2(3H)-one,
l-(6-Methoxy-2-methylpyridin-3-yl)-3-methyl-8-(5-(trifluoromethyl)pyridin-3-yl)-lHimidazo[
4,5-c]quinolin-2(3H)-one,
8-(6-(Dimethylamino) pyridin-3-yl)-l-(6-methoxy-2-methylpyridin-3-yl)-3-methyl-lHimidazo[
4,5-c] quinolin-2(3H)-one,
l-(6-Methoxy-2-methylpyridin-3-yl)-3-methyl-8-(quinolin-3-yl)-lH-imidazo[4,5-c]quinoH
2(3H)-one,
5-(3-(Cyanomethyl)-2-oxo-8-(pyridin-3-yl)-2,3-dihydro- lH-imidazo[4,5-c]quinolin- 1-
yl)picolinonitrile,
5-(3-(l-Cyanoethyl)-2-oxo-8-(pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-lyl)
picolinonitrile,
5-(3-Methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-l-yl)
picolinonitrile,
5-(8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lHimidazo[
4,5-c]quinolin- 1-yl)picolinonitrile,
5-(8-(2-Fluoropyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-l-yl)
picolinonitrile,
5-(8-(6-Fluoropyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro- lH-imidazo[4,5-c]quinolin- 1-yl)
picolinonitrile,
5-(8-(6-Methoxypyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-lyl)
picolinonitrile,
5-(3-Methyl-2-oxo-8-(pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-l-yl)
picolinonitrile,
5-(8-(6-(Dimethylamino)pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)picolinonitrile,
5-(3-(Cyanomethyl)-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-lyl)
picolinonitrile,
5-(3-(l-Cyanoethyl)-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-lyl)
picolinonitrile,
3-Methyl-8-(pyridin-3-yl)-l-(6-(trifluoromethyl)pyridin-3-yl)-lH-imidazo[4,5-c]quin^
2(3H)-one,
3-Methyl-8-(quinolin-3-yl)-l-(6-(trifluoromethyl)pyridin-3-yl)-lH-imidazo[4,5-c]qum^
2(3H)-one,
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-m
lH-imidazo[4,5-c]quinolin-2(3H)-one,
3-Methyl-l,8-bis(6-(nifluoromethyl)pyridin-3-yl)-lH-imidazo[4,5-c]quinolin-2(3H^
8-(2,6-Difluoropyridin-3-yl)-3-methyl-l-(6-(trifluoromethyl)pyridin-3-yl)-lH-im^
c]quinolin-2(3H)-one,
6-Chloro-5-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-lyl)
picolinonitrile,
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)- 1-(2-chloro-6-(trifluoromethyl) pyridin-3-yl)-3-
methyl- lH-imidazo[4,5-c]quinolin-2(3H)-one,
l-(6-Chloropyridin-3-yl)-3-methyl-8-(pyridin-3-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-one,
l-(6-Chloropyridin-3-yl)-3-methyl-8-(quinolin-3-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-one,
l-(2,6-Dichloropyridin-3-yl)-3-methyl-8-(pyridin-3-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-
one,
l-(6-Chloro-2-(trifluoromethyl)pyridin-3-yl)-3-methyl-8-(pyridin-3-yl)-lH-imidazo[4,5-
c]quinolin-2(3H)-one,
l-(6-(Dimethylamino)pyridin-3-yl)-3-methyl-8-(quinolin-3-yl)-lH-imidazo[4,5-c]quinolin-
2(3H)-one,
3-Methyl-8-(quinolin-3-yl)-l-(quinolin-6-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-one,
3-Methyl- l-(quinolin-6-yl)-8-(5-(trifluoro^
2(3H)-one,
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-methyl- 1-(quinolin-6-yl)- 1H-imidazo[4,5-
c]quinolin-2(3H)-one,
3-Methyl-l-(2-morpholinoethyl)-8-(pyridin-3-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-one,
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-methyl-l-(2-morpholinoethyl)-lHimidazo[
4,5-c]quinolin-2(3H)-one,
3-Methyl-l-(2-morpholinoethyl)-8-(quinolin-3-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-one,
3-Methyl- 1-(6-(4-methylpiperazin- 1-yl)pyridin-3-yl)-8-(pyridin-3-yl)- lH-imidazo[4,5-
c]quinolin-2(3H)-one,
l-(6-Chloro-2,4'-bipyridin-3-yl)-3-methyl-8-(pyridin-3-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-
one,
3-Methyl- l-(6-morpholinopyridin-3-yl)-8-(quinolin-3-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-
one,
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-methyl- 1-(2-(trifluoromethyl) pyrimidin-5-
yl)-lH-imidazo[4,5-c]quinolin-2(3H)-one and
8-(5-Amino-6-methoxypyridin-3-yl)-l-(6-methoxypyridin-3-yl)-3-methyl-lH-imidazo[4,5-
c]quinolin-2(3H)-one or
a pharmaceutically acceptable salt, a stereoisomer, a tautomer or N-oxide thereof.
Particular compounds encompassed in accordance with the present invention include:
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-l-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-3-
methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-5-ium methanesulfonate,
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-l-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-3-
methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-5-ium chloride,
8-(Isoquinolin-4-yl)- l-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydrolH-
imidazo[4,5-c]quinolin-5-ium methanesulfonate,
8-(Isoquinolin-4-yl)- l-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydrolH-
imidazo[4,5-c]quinolin-5-ium chloride,
8-(6-Ammonio-5-(trifluoromethyl)pyridin-3-yl)-l-(6-methoxypyridin-3-yl)-3-methyl-2-oxo-
2,3-dihydro-lH-imidazo[4,5-c]quinolin-5-ium methanesulfonate and
8-(6-Ammonio-5-(trifluoromethyl)pyridin-3-yl)-3-methyl-2-oxo-l-(6-(trifluoromethyl)
pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-5-ium methanesulfonate,
or a stereoisomer, a tautomer or an N-oxide thereof.
METHODS OF PREPARATION
The compounds of formula (I) can be prepared using various procedures, some of
which are depicted in the scheme below. Those with skill in the art will appreciate that the
specific starting compounds and reagents, such as bases, solvents, coupling agents;
temperature conditions etc. identified in the Scheme can be altered to prepare compounds
encompassed by the present invention.
Scheme 1
(V) (8)
wherein ¾ , R2 and R3 are as defined in any one of the embodiments of the invention for the
compounds of formula (I).
As illustrated in scheme 1, the compound of formula (2), can be prepared by reacting
nitromethane in the presence of a base such as NaOH in the temperature range from 0 °C to
RT; then adding the product to cone. HC1 at about 0-10 °C and adding the compound of the
formula (1) in aqueous acid such as water-HCl mixture, and stirring at a temperature ranging
from about 0 °C to RT. The nitro compound of formula (2) can be reacted with an acid
anhydride such as acetic anhydride in the presence of an alkali metal salt such as potassium
acetate or sodium acetate at a temperature ranging from about 80-140 °C to form a compound
of formula (3). The nitro-quinolinol compound of formula (3) can be treated with a
halogenating agent, for example with a chlorinating agent such as POCI 3 at a temperature
ranging from about 80-140 °C to form a compound of formula (4). The compound of formula
(4) can be treated with an amine of formula R1-NH2 at a temperature range from about 0-40
°C to form a compound of formula (5), wherein R is as defined in any one of the
embodiments of the invention for the compounds of formula (I). Catalytic reduction of nitro
group of compound of formula (5) forms quinoline-diamine of formula (6). The quinolinediamine
of formula (6) can be reacted with a reagent such as trichloromethylchloroformate or
triphosgene in the presence of a base such as triethylamine or trimethylamine in an
appropriate solvent such as dichloromethane or chloroform to form a compound of formula
(7). The compound of formula (7) can be treated with a compound of formula R2-hal,
wherein hal is halogen and R2 is as defined in any one of the embodiments of the invention
for the compounds of formula (I), in the presence of a base such as sodium hydride to form a
compound of formula (8). The compound of formula (8) can be further treated with a
compound of formula R -B(OH)2 in the presence of a coupling agent such as palladium
dichlorobistriphenylphosphme and a base such as sodium carbonate to form a compound of
formula (I), wherein Ri, R2 and R3 are as defined in any one of the embodiments of the
invention for the compounds of formula (I).
The process of the present invention described herein comprises an optional step of
forming a salt and/or a solvate and/or a prodrug of the compound of formula (I).
Isotopically labeled forms of compounds of formula (I) can be prepared by
conventional techniques known to those skilled in the art or by processes analogous to those
described above and in the subsequent Exemplification section by using an appropriate
isotopically labeled reagent instead of non-labeled reagent.
The pharmaceutically acceptable salts of the present invention can be synthesized
from the subject compound (the compound of formula I), which contains a basic or an acidic
moiety, by conventional chemical methods. Generally the salts are prepared by contacting the
free base or acid with an appropriate amount of the desired salt-forming inorganic or organic
acid or base in a suitable solvent or dispersant, or by cation or anion exchange. Suitable
solvents are, for example, ethyl acetate, ether, alcohols, acetone, tetrahydrofuran, dioxane or
mixtures of these solvents. These solvents can also be used for purification of the compounds
obtained.
According to a further aspect of the present invention, there is provided a process for
the preparation of a compound of formula (I) and its pharmaceutically acceptable salt.
According to a further aspect of the present invention, there is provided a process for
the preparation of a compound of formula (7), wherein R is defined in any one of the
embodiments of the invention for the com ounds of formula (I)
(7)
comprising,
reacting a compound of formula (6);
(6)
with a reagent such as trichloromethylchloroformate or triphosgene in the presence of a base
such as triethylamine or trimethylamine, wherein, R is as defined in any one of the
embodiments of the invention for the compounds of formula (I).
According to a further aspect of the present invention, there is provided a process for
the preparation of a compound of formula (8), wherein R and R2 are as defined for
formula (I),
comprising,
reacting a compound of formula (7);
(7)
with a compound of formula R2-hal, wherein hal is halogen and R2 is as defined in any one of
the embodiments of the invention for the compounds of formula (I) in the presence of a base
such as sodium hydride, wherein, R is as defined in any one of the embodiments of the
invention for the compounds of formula (I).
According to a further aspect of the present invention, there is provided a process for
the preparation of a compound of
comprising,
reacting a compound of formula (8)
with a compound of formula R -B(OH)2 in the presence of a coupling agent such as palladium
dichlorobistriphenylphosphine, wherein R and R2 are as defined in any one of the
embodiments of the invention for the compounds of formula (I).
The compounds of formula (I) can be converted to corresponding pharmaceutically
acceptable salts.
METHODS OF TREATMENT
The term "treat or treating or treatment" means decrease, suppress, attenuate,
diminish, arrest, or stabilize the development or progression of a disease (e.g., a disease or
disorder delineated herein), lessen the severity of the disease or improve the symptoms
associated with the disease.
"Disease" means any condition or disorders that damage or interferes with the normal
function of a cell, tissue, or organ.
As used herein, the term "therapeutically effective amount" refers to an amount of the
compound of formula (I) which, when administered to a subject in need thereof in a proper
dosing regimen, is sufficient to treat the target disease or disorder as described herein.
The term "subject" as used herein, refers to an animal, preferably a mammal, most
preferably a human, who has been the object of treatment, observation or experiment.
The term "mammal" used herein refers to warm-blooded vertebrate animals of the
class mammalia, including humans, characterized by a covering of hair on the skin and, in the
female, milk-producing mammary glands for nourishing the young. The term mammal
includes animals such as cat, dog, rabbit, bear, fox, wolf, monkey, deer, mouse, pig as well as
human.
Compounds of the present invention inhibit one or more kinases associated with the
proliferative diseases or disorders. The kinases associated with proliferative diseases include,
but are not limited to PI3K, mTOR, DNA-PK, MAP4K2, ALK1, ALK2, CLK1, CLK4,
JAK2, MAP4K5, MuSK, RIPK2 and ROS.
The present invention further provides a method for the treatment of diseases or
disorders that can be treated by inhibiting one or more isoforms of PI3K, including PBKa,
RBKb, RBKd and RBKg.
Proliferative disease or disorder that can be treated by the compounds of formula (I) is
cancer, including, but not limited to leukemia such as acute lymphocytic leukemia; acute
myeloid leukemia; adult acute myeloid leukemia; acute lymphoblastic leukemia; chronic
lymphocytic leukemia; chronic myeloid leukemia; hairy cell leukemia, lung cancer including
non-small-cell lung cancer and small-cell lung cancer, brain tumors such as brain stem
glioma; glioblastoma; astrocytoma including cerebellar astrocytoma and cerebral
astrocytoma; visual pathway and hypothalamic glioma, supratentorial primitive
neuroectodermal and pineal tumors; medulloblastoma, lymphoma such as primary central
nervous system lymphoma; non-Hodgkin's lymphoma particularly mantle cell lymphoma,
Hodgkin's disease, liver cancer such as hepatocellular carcinoma, kidney cancer such as renal
cell carcinoma and Wilms' tumor, sarcoma such as Ewing's sarcoma family of tumors;
osteosarcoma; Rhabdomyosarcoma; soft tissue sarcomas, mesothelioma, bladder cancer,
breast cancer, endometrial cancer, head and neck cancer such as oral cancer; esophageal
cancer, melanoma, cervical cancer, thyroid cancer, gastric cancer, germ cell tumor,
cholangiocarcinoma, extracranial cancer, malignant fibrous histiocytoma of bone,
retinoblastoma, multiple myeloma, pancreatic cancer, ependymoma, neuroblastoma, skin
cancer, ovarian cancer, recurrent ovarian cancer, prostate cancer, testicular cancer, colorectal
cancer, lymphoproliferative disease, refractory multiple myeloma, resistant multiple
myeloma and myeloproliferative disorder, or a combination of one or more of the preceding
cancers.
As such, compounds of the present invention can be used to treat tumor cells, and
thereby assist in reducing the size of a tumor.
Compounds of the present invention inhibit TNF-a, IL-6 or VEGF associated with
inflammatory diseases or disorders and angiogenesis related diseases or disorders.
Inflammatory diseases or disorders that can be treated by the compounds of formula
(I) include, but are not limited to, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic
arthritis, osteoarthritis, refractory rheumatoid arthritis, chronic non-rheumatoid arthritis,
osteoporosis, bone resorption, septic shock, Crohn's disease, inflammatory bowel disease,
ulcerative colitis, atherosclerosis and psoriasis.
Compounds of the present invention may also be used for the treatment of other
diseases or conditions, such as inflammatory or allergic conditions of the skin, for example,
contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforme, dermatitis
herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid,
lupus erythematosus, pemphigus, epidermolysis bullosa acquisita, skin delayed type
hypersensitivity disorders; cardiovascular diseases, for example, atherosclerosis, ischaemiareperfusion
injury, coronary heart disease; neural diseases, for example, multiple sclerosis,
Alzheimer's disease), sepsis, chronic recurrent uveitis, hepatitis C virus infection, viral
infection, bacterial infection, fungal infection, malaria, ulcerative colitis, cachexia,
plasmocytoma, endometriosis, Behcet's disease, Wegenrer's granulomatosis, AIDS, HIV
infection, autoimmune disease, immune deficiency, common variable immunodeficiency
(CVID), chronic graft-versus-host disease, trauma and transplant rejection, adult respiratory
distress syndrome, pulmonary fibrosis, chronic obstructive pulmonary disease, bronchitis,
metabolic disorders (such as diabetes and juvenile diabetes), meningitis, ankylosing
spondylitis, systemic lupus erythematosus, allergic asthma, inflammation, septic shock,
endotoxic shock, vasculitis and amyloidosis.
Compounds of the present invention can be used for the treatment of angiogenesis
related diseases or disorders.
Compounds of the present invention may also be used for the treatment of diseases in
which angiogenesis is believed to be important, referred to as angiogenic diseases, including
but not limited to, inflammatory disorders such as immune and non-immune inflammation,
chronic articular rheumatism, psoriasis, disorders associated with inappropriate or
inopportune invasion of vessels such as diabetic retinopathy, neovascular glaucoma, capillary
proliferation in atherosclerotic plaques and osteoporosis, and cancer associated disorders,
such as solid tumors, solid tumor metastases, angiofibromas, retrolental fibroplasia,
hemangiomas, Karposi's sarcoma and the like cancers which require neovascularization to
support tumor growth.
The following abbreviations and definitions are used throughout this application:
The term "tumor" as used herein refers to an abnormal growth of tissue resulting from
uncontrolled, progressive multiplication of cells. A tumor can be benign or malignant.
Abbreviations:
PI3 kinase phosphatidylinositol-3 -kinase
mTOR mammalian target of rapamycin
DNA-PK DNA-dependent protein kinase
MAP4K2 mitogen-activated protein kinase kinase kinase kinase 2
ALK1 (also known as ACVRL1) activin receptor-like kinase 1
ALK2 (also known as ACVR1) activin A receptor, type I
CLK1 CDC-like kinase 1
CLK4 CDC-like kinase 4
JAK2 Janus kinase 2
MAP4K5 mitogen-activated protein kinase kinase kinase kinase 5
MuSK muscle-specific receptor tyrosine kinase
RIPK2 receptor-interacting serine/threonine-protein kinase 2
ROS reactive oxygen species
According to another aspect of the present invention, there is provided a method of
treating diseases or disorders selected from proliferative diseases, inflammatory diseases or
disorders or angiogenesis related diseases or disorders in a subject, comprising administering
to the subject a therapeutically effective amount of a compound of formula (I) or a
stereoisomer or a tautomer, or an N-oxide or a pharmaceutically acceptable salt or a solvate
thereof.
According to another aspect of the present invention, there is provided a method of
treating diseases or disorders mediated by one or more kinases selected from CLK- 1, CLK-4,
DNA-PK, MAP4K2, MAP4K5 or RIPK2 in a subject, comprising administering to the
subject a therapeutically effective amount of a compound of formula (I) or a
pharmaceutically acceptable salt thereof.
According to another aspect of the present invention, there is provided a method of
treating diseases or disorders mediated by one or more kinases selected from PI3K, mTOR,
ALK-1 or ALK-2 in a subject, comprising administering to the subject a therapeutically
effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
According to another aspect of the present invention there is provided a method of
inhibiting activity of kinases selected from PI3K, mTOR, ALK-1 or ALK-2 comprising
contacting the kinase with an effective amount of a compound of formula (I).
According to another aspect of the present invention, there is provided a method of
treating diseases mediated by VEGF in a subject, comprising administering to the subject a
therapeutically effective amount of a compound of formula (I) or a pharmaceutically
acceptable salt thereof.
According to another aspect of the present invention there is provided a method of
inhibiting VEGF, comprising contacting VEGF with an effective amount of a compound of
formula (I).
According to further aspect of the present invention, there is provided a method for
the treatment of diseases mediated by TNF-a or IL-6 in a subject, comprising administering
to the subject a therapeutically effective amount of a compound of formula (I) or a
pharmaceutically acceptable salt thereof.
According to another aspect of the present invention there is provided a method for
inhibiting TNF- a or IL-6, comprising contacting TNF- a or IL-6 with an effective amount of
a compound of formula (I).
According to another aspect of the present invention, there is provided a method of
treating proliferative diseases or disorders, inflammatory diseases or disorders or
angiogenesis related diseases or disorders mediated by one or more kinases selected from PI3
kinase, mTOR, ALK-1 or ALK-2, comprising administering to a subject in need thereof a
therapeutically effective amount of a compound of formula (I) or a pharmaceutically
acceptable salt thereof.
According to another aspect of the present invention, there is provided a method for
the treatment of proliferative diseases or disorders mediated by one or more kinases, selected
from PI3K, mTOR, ALK-1 or ALK-2 in a subject, comprising administering to the subject a
therapeutically effective amount of a compound of formula (I) or a pharmaceutically
acceptable salt thereof.
According to another aspect of the present invention, there is provided a compound of
formula (I) or a stereoisomer, a tautomer, an N-oxide, a pharmaceutically acceptable salt or a
solvate thereof, for use in the treatment of diseases or disorders selected from proliferative
diseases or disorders, inflammatory diseases or disorders or angiogenesis related diseases or
disorders.
According to another aspect of the present invention, there is provided a compound of
formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of diseases
or disorders mediated by one or more kinases selected from CLK-1, CLK-4, DNA-PK,
MAP4K2, MAP4K5 or RIPK2.
According to another aspect of the present invention, there is provided a compound of
formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of diseases
or disorders mediated by one or more kinases selected from PI3K, mTOR, ALK-1 or ALK-2.
According to further aspect of the present invention, there is provided a compound of
formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of diseases
mediated by TNF-a or IL-6.
According to another aspect of the present invention, there is provided a compound of
formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of diseases
mediated by VEGF.
According to another aspect of the present invention, there is provided a compound of
formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of
proliferative diseases, inflammatory diseases or angiogenesis related disorders mediated by
one or more kinases selected from PI3K, mTOR, ALK-1 or ALK-2.
According to another aspect of the present invention, there is provided a compound of
formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of
proliferative diseases or disorders mediated by one or more kinases, such as PI3K, mTOR,
ALK-1 or ALK-2.
According to another aspect of the present invention, the proliferative disease
mediated by one or more kinases is cancer.
According to another aspect of the present invention, the cancer is solid cancer or
hematological cancer.
According to another embodiment of the present invention, the cancer is selected
from: leukemia such as acute lymphocytic leukemia; acute myeloid leukemia; adult acute
myeloid leukemia; acute lymphoblastic leukemia; chronic lymphocytic leukemia; chronic
myeloid leukemia; hairy cell leukemia, lung cancer including non-small-cell lung cancer and
small-cell lung cancer, brain tumors such as brain stem glioma; glioblastoma; astrocytoma
including cerebellar astrocytoma and cerebral astrocytoma, visual pathway and hypothalamic
glioma; supratentorial primitive neuroectodermal and pineal tumors; medulloblastoma,
lymphoma such as primary central nervous system lymphoma; non-Hodgkin's lymphoma
particularly mantle cell lymphoma, Hodgkin's disease, liver cancer such as hepatocellular
carcinoma, kidney cancer such as renal cell carcinoma and Wilms' tumor, sarcoma such as
Ewing's sarcoma family of tumors; osteosarcoma; rhabdomyosarcoma; soft tissue sarcomas,
mesothelioma, bladder cancer, breast cancer, endometrial cancer, head and neck cancer,
melanoma, cervical cancer, thyroid cancer, gastric cancer, germ cell tumor,
cholangiocarcinoma, extracranial cancer, malignant fibrous histiocytoma of bone,
retinoblastoma, esophageal cancer, multiple myeloma, oral cancer, pancreatic cancer,
ependymoma, neuroblastoma, skin cancer, ovarian cancer, recurrent ovarian cancer, prostate
cancer, testicular cancer, colorectal cancer, lymphoproliferative disease, refractory multiple
myeloma, resistant multiple myeloma or myeloproliferative disorder, or a combination of
one or more of the preceding cancers.
According to another embodiment of the present invention, the cancer is selected
from leukemia, lung cancer, brain tumors, Hodgkin's disease, liver cancer, kidney cancer,
bladder cancer, breast cancer, head and neck cancer, endometrial cancer, lymphoma,
melanoma, cervical cancer, thyroid cancer, gastric cancer, germ cell tumor,
cholangiocarcinoma, extracranial cancer, sarcoma, mesothelioma, malignant fibrous
histiocytoma of bone, retinoblastoma, esophageal cancer, multiple myeloma, oral cancer,
pancreatic cancer, neuroblastoma, skin cancer, ovarian cancer, recurrent ovarian cancer,
prostate cancer, testicular cancer, colorectal cancer, lymphoproliferative disease, refractory
multiple myeloma, cancer of urinary tract, resistant multiple myeloma or myeloproliferative
disorder.
According to another embodiment of the present invention, the cancer is selected
from breast cancer, prostate cancer, pancreatic cancer, lung cancer, head and neck cancer,
ovarian cancer, colorectal cancer, kidney cancer, gastric cancer, non-Hodgkin's lymphoma,
primary central nervous system lymphoma, endometrial cancer, brain tumor, melanoma, liver
cancer, thyroid cancer, lymphoid cancer, esophageal cancer, cancer of urinary tract, cervical
cancer, bladder cancer, mesothelioma, sarcoma or chronic myeloid leukemia.
According to another embodiment of the present invention, the cancer is selected
from ovarian cancer, prostate cancer, breast cancer, pancreatic cancer, brain tumors or
chronic myeloid leukemia.
According to another aspect of the present invention, there is provided a method for
the treatment of inflammatory diseases or disorders mediated by one or more kinases,
including, but not limited to, PI3K and mTOR, comprising administering to a subject in need
thereof a therapeutically effective amount of a compound of formula (I) or a
pharmaceutically acceptable salt thereof.
According to further aspect of the present invention, there is provided a method for
the treatment of inflammatory diseases mediated by TNF-a or IL-6 in a subject, comprising
administering to the subject a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof.
According to another aspect of the present invention, there is provided a compound of
formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of
inflammatory diseases or disorders mediated by one or more kinases, including, but not
limited to, PI3K and mTOR.
According to further aspect of the present invention, there is provided a compound of
formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of
inflammatory diseases or disorders mediated by TNF-a or IL-6.
According to another aspect of the present invention, the inflammatory diseases or
disorders are selected from rheumatoid arthritis, Crohn's disease, ulcerative colitis,
inflammatory bowel disease, chronic non-rheumatoid arthritis, osteoporosis, septic shock,
psoriasis or atherosclerosis.
According to another aspect of the present invention, there is provided a method of
treating angiogenesis related disorders mediated by one or more kinases, including but not
limited to, PI3K, mTOR, ALK-1 or ALK-2 in a subject, comprising administering to the
subject a therapeutically effective amount of a compound of formula (I) or a
pharmaceutically acceptable salt thereof.
According to another aspect of the present invention, there is provided a method of
treating angiogenesis related disorders mediated by VEGF in a subject, comprising
administering to the subject a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof.
According to another aspect of the present invention, there is provided a compound of
formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of
angiogenesis related disorders mediated by one or more kinases, including but not limited to,
PI3K, mTOR, ALK-1 or ALK-2.
According to another aspect of the present invention, there is provided a compound of
formula (I) or a pharmaceutically acceptable salt thereof; for use in the treatment of
angiogenesis related disorders mediated by VEGF.
According to another aspect of the present invention, the angiogenesis related disorder
is an inflammatory disorder.
According to another aspect of the present invention, the inflammatory disorder which
is an angiogenesis related disorder is selected from immune and non-immune inflammation,
chronic articular rheumatism, disorders associated with inappropriate or inopportune invasion
of vessels such as diabetic retinopathy, neovascular glaucoma, capillary proliferation in
atherosclerotic plaques or osteoporosis.
According to another aspect of the present invention, the angiogenesis related disorder
is cancer associated disorder, such as solid tumor, solid tumor metastasis, angiofibroma,
retrolental fibroplasia, hemangioma or Kaposi's sarcoma.
According to another aspect of the present invention, the anti-angiogenic potential of
the compounds of the present invention can be determined using zebra fish assay by
following the protocol as described in Nature Protocols, 2007, , 2918- 2923.
According to another aspect of the present invention, there are provided methods for
the manufacture of medicaments comprising compounds of formula (I) or pharmaceutically
acceptable salts thereof, which are useful for the treatment of cancers.
According to another aspect of the present invention, there are provided methods for
the manufacture of medicaments, comprising compounds of formula (I) or pharmaceutically
acceptable salts thereof, which are useful for the treatment of angiogenesis related diseases or
disorders.
According to another aspect of the present invention, there are provided methods for
the manufacture of medicaments, comprising compounds of formula (I) or pharmaceutically
acceptable salts thereof, which are useful for the treatment of inflammatory diseases or
disorders.
Additionally, the present invention provides a compound of formula (I) or a
stereoisomer, a tautomer, an N-oxide or a pharmaceutically acceptable salt thereof, for use in
the treatment of the human or animal body.
PHARMACEUTICAL COMPOSITIONS
The pharmaceutical preparations according to the invention are prepared in a manner
known per se and familiar to one skilled in the art. Pharmaceutically acceptable inert
inorganic and/or organic carriers and/or additives can be used in addition to the compounds
of formula (I), and/or their pharmaceutically acceptable salts. For the production of pills,
tablets, coated tablets and hard gelatin capsules it is possible to use, for example, lactose,
corn starch or derivatives thereof, gum acacia, magnesia or glucose, etc. Carriers for soft
gelatin capsules and suppositories are, for example, fats, waxes, natural or hardened oils, etc.
Suitable carriers for the production of solutions, for example injection solutions, or for
emulsions or syrups are, for example, water, physiological sodium chloride solution or
alcohols, for example, ethanol, propanol or glycerol, sugar solutions, such as glucose
solutions or mannitol solutions, or a mixture of the various solvents which have been
mentioned.
The pharmaceutical preparations normally contain about 1 to 99 %, for example,
about 5 to 70%, or from about 5 to about 30 % by weight of the compound of formula (I) or
pharmaceutically acceptable salt thereof. The amount of the compound of formula (I) or
pharmaceutically acceptable salt thereof in the pharmaceutical preparations normally is from
about 1 to 1000 mg.
The dose of the compounds of this invention, which is to be administered, can cover a
wide range. The dose to be administered daily is to be selected to produce the desired effect.
A suitable dosage is about 0.01 to 100 mg/kg of the compound of formula (I) or
pharmaceutically acceptable salt thereof, for example, about 0.01 to 20 mg/kg of a compound
of formula (I) or a pharmaceutically acceptable salt thereof, with the typical dose being about
0.1 to 5 mg/kg of a compound of formula (I) or a pharmaceutically acceptable salt thereof. If
required, higher or lower daily doses can also be administered. Actual dosage levels of the
active ingredients in the pharmaceutical compositions of this invention may be varied so as to
obtain an amount of the compound of formula (I), which is effective to achieve the desired
therapeutic response for a particular subject.
The pharmaceuticals can be administered orally, for example in the form of pills,
tablets, coated tablets, lozenges, capsules, dispersible powders or granules, suspensions,
emulsions, syrups or elixirs. Administration, however, can also be carried out rectally, for
example in the form of suppositories, or parenterally, for example intravenously,
intramuscularly or subcutaneously, in the form of injectable sterile solutions or suspensions,
or topically, for example in the form of solutions or ointments or transdermally, for example
in the form of transdermal patches, or in other ways, for example in the form of aerosols,
nasal sprays or nasal drops.
The selected dosage level will depend upon a variety of factors including the activity
of the particular compound of the present invention employed, the route of administration,
the time of administration, the rate of excretion of the particular compound being employed,
the duration of the treatment, other drugs, compounds and /or materials used in combination
with the particular compounds employed, the age, sex, weight, condition, general health and
prior medical history of the patient being treated, and like factors well known in the medical
arts.
In addition to the compound of formula (I) and/or its pharmaceutically acceptable salt
and carrier substances, the pharmaceutical preparations can contain additives such as, for
example, fillers, antioxidants, dispersants, emulsifiers, defoamers, flavors, preservatives,
solubilizers or colorants. They can also contain one or more compounds of formula (I) and/or
their pharmaceutically acceptable salts. Furthermore, in addition to at least one compound of
formula (I) and/or its pharmaceutically acceptable salt, the pharmaceutical preparations can
also contain one or more other therapeutically or prophylactically active ingredients.
By "pharmaceutically acceptable" it is meant the carrier, diluent, excipients, and/or
salt must be compatible with the other ingredients of the formulation, and not deleterious to
the recipient thereof.
According to another aspect of the present invention there is provided a
pharmaceutical composition, comprising a therapeutically effective amount of a compound of
formula (I) or a pharmaceutically acceptable salt thereof in association with a
pharmaceutically acceptable excipient or carrier.
According to another aspect of the present invention there is provided any of the uses,
methods or compositions as defined above wherein the compound of formula (I), or
pharmaceutically acceptable salt thereof, is used in combination with another
pharmacologically active compound, particularly one of the compounds listed herein below.
A compound of formula (I) may be administered either simultaneously or before or
after the pharmacologically active compound, either separately by the same or different route
of administration, or together in the same pharmaceutical formulation.
According to another aspect of the present invention there is provided a
pharmaceutical composition, comprising a therapeutically effective amount of a compound of
formula (I) or a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate
thereof and at least one further pharmaceutically active compound, together with a
pharmaceutically acceptable excipient or carrier. A pharmaceutically active compound in
combination with one or more compounds of formula (I) for treatment of cancer can be
selected from, but not limited to, one or more of the following groups: (i) Kinase inhibitors
such as gefitinib, imatinib, erlotinib, lapatinib, bevacizumab (avastin), sorafenib, Bcr-Abl
kinase inhibitors or LY- 317615 (ii) Alkylating agents such as mitomycin C, busulfan,
oxaliplatin, cisplatin, carboplatin, procarbazine or dacarbazine (iii) Antimetabolites such as
methotrexate, mercaptopurine, thioguanine, fludarabine phosphate, fluorouracil, vinblastine,
vincristine, gemcitabine or paclitaxel (iii) Antibiotics such as anthracyclines, dactinomycin or
bleomycin (iv) Hormonal agents such as tamoxifen, flutamide, GnRH (Gonadotropin-
Releasing Hormone) agonists or aromatase inhibitors or (v) Cancer vaccines such as avicine,
oregovomab or theratope.
It is understood that modifications that do not substantially affect the activity of the
various embodiments of this invention are included within the invention disclosed herein.
Accordingly, the following examples are intended to illustrate but not to limit the present
invention.
EXEMPLIFICATION
Synthetic Methods
The invention is further understood by reference to the following examples, which are
intended to be purely exemplary of the invention. The present invention is not limited in
scope by the exemplified embodiments, which are intended as illustrations of single aspects
of the invention only. Any methods that are functionally equivalent are within the scope of
the invention. Various modifications of the invention in addition to those described herein
will become apparent to those skilled in the art from the foregoing description. Such
modifications fall within the scope of the appended claims. For example, the synthesis of
non-exemplified compounds according to the invention may be successfully performed by
modifications apparent to those skilled in the art.
Nomenclature of the compounds exemplified in the present invention was derived
from Chemdraw Ultra version 9.0.1 CambridgeSoft Corporation, Cambridge.
Reagents were purchased from commercial suppliers such as Sigma Aldrich Chemical
company, Spectrochem Ltd., India; AK scientific Inc. CA, Thomas Baker (Chemicals) Pvt.
Ltd., India; Merck KgaA, Darmstadt, Germany and are used as such.
Unless otherwise stated all temperatures are in degree Celsius. Also, in these
examples and elsewhere, abbreviations have the following meanings:
List of abbreviations
ATCC American Type Culture GST glutathione S-Transferase
Collection
ATP Adenosine triphosphate mM micro Molar
BSA Bovine Serum Albumin ng nanogram
co2 Carbon dioxide nM nanoMolar
CHC1 Chloroform pM picoMolar
CDCI3 Deuterated chloroform MOPSO 3-(N-Morpholino)-2-
hydroxypropanesulfonic Acid
cpm Counts per minute NaCl Sodium chloride
DCM Dichloromethane NaH Sodium hydride
DMF Dimethyl formamide Na2C0 Sodium carbonate
DMSO Dimethyl sulfoxide NaF Sodium Fluoride
DTT Dithiothreeitol NaHCC- Sodium bicarbonate
EDTA Ethylene Diamine NaOH Sodium hydroxide
Tetraacetic Acid
EGTA Ethylene Glycol Na2S0 4 Sodium sulfate
Tetraacetic Acid
EtOAc Ethyl acetate Ni Nickel
ELISA Enzyme-Linked NP-40 Nonidet P40
Immunosorbent Assay
FCS Fetal Calf Serum psi pound per square inch
g Gram POCI3 Phosphorus oxychloride
HC1 Hydrochloric acid PBS Phosphate buffer saline
IL-6 Interleukin 6 RT Room Temperature (20-30 °C)
IFN-g Interferon- g RPMI Roswell Park Memorial Institute
MgCl2 Magnesium chloride SDS-PAGE Sodium dodecyl sulfate
Polyacrylamide Gel Electrophoresis
MeOH Methanol TBS Tris Buffered Saline
microgram TBST Tween Tris buffer saline
mΐ microliter THF Tetrahydrofuran
mL Milliliter TNF-a Tumor necrosis factor a
mM or milliMolar VEGF Vascular Endothelial Growth Factor
mmol
mg milligram
INTERMEDIATES
Intermediate 1: 6-bromo-4-chloro-3-nitroquinoline
A: 5-bromo-2-(2-nitrovinylamino)benzoic acid
A suspension of 2-amino-5-bromobenzoic acid (231 mmol) in water-HCl (37 %) (10:1) was
stirred for 8 hours and was filtered (solution 1). Nitromethane (278 mmol) was added over 10
minutes to a mixture of ice (70 g) and NaOH (775 mmol) at 0 °C under stirring. After stirring
for 1 hour at 0 °C and 1 hour at RT, this solution was added to a mixture of ice (56 g) and 84
mL of HCl (37 %) at 0 °C (solution 2). Solution 1 and 2 were combined and the reaction
mixture was stirred for 18 hours at RT. The yellow precipitate was filtered, washed with
water and dried at 40 °C to obtain the title compound. The crude product was used directly
for the next step. Yield: 38 %.
B: 6-bromo-3-nitroquinolin-4-ol
5-bromo-2-(2-nitrovinylamino)benzoic acid (Compound A, 87 mmol) and potassium acetate
(104 mmol) in acetic anhydride ( 1185 mmol) were stirred for 3 hours at 120 °C. The
precipitate was filtered, and washed with acetic acid until the filtrate was colorless. It was
further washed with water and dried to obtain the title compound H NMR (500 MHz,
CDC1 ) : d 9.275 (s, 1H), 8.61 1-8.615 (d, 1H, J= 2Hz), 8.100-8.1 18 (d, 1H, J=9Hz), 8.026-
8.048 (dd, 1H, J= 8.5Hz, 2Hz).
C: 6-bromo-4-chloro-3-nitroquinoline
6-bromo-3-nitroquinolin-4-ol (compound B, 74.3 mmol) and POCI 3 (1613 mmol) were stirred
for 45 minutes at 120 °C. The mixture was cooled to RT and poured slowly into ice-water.
The precipitate was filtered, washed with ice-cold water, and dissolved in DCM. The organic
layer was washed with cold brine, and was dried over Na2S0 4. The solvent was evaporated to
dryness to obtain the title compound. The crude product was used directly for the next step.
Intermediate 2 : 2-(5-aminopyridin-2-yl)-2-methylpropanenitrile
A: 2-methyl-2-(5-nitropyridin-2-yl)propanenitrile
Sodium hydride (67.44 mmol) was added to a solution of 2-(5-nitropyridine-2-yl) acetonitrile
(30.65 mmol) in dry THF (250 mL) at 0 °C and the reaction mixture was stirred for 0.5 hours.
Methyl iodide (91.95 mmol) was added to the reaction mixture and reaction mixture was
warmed to RT, stirred for another 24 hours. Solvent was removed under vacuum; crude
product was purified (silica gel column, EtOAc/hexane as eluent) to obtain the title
compound. H NMR (300 MHz, DMSO-d6) : d 9.43 (d, J=2.7 Hz, 1H), 8.55 (dd, J=8.7, 2.4
Hz, 1H), 7.86 (d, J = 8.7 Hz, 1H), 1.82 (s, 6H); MS (m/z): 192 (M+l) +.
B: 2-(5-aminopyridin-2-yl)-2-methylpropanenitrile
2-methyl-2-(5-nitropyridin-2-yl)propanenitrile (15.70 mmol) was subjected to hydrogenation
using Raney-Ni (0.6 g) at 40 psi for 4 hours. Reaction mixture was filtered and washed with
methanol. Filtrate was concentrated and purified (silica gel column, MeOH/CHC¾ as eluent)
to obtain the title compound. H NMR (300 MHz, DMSO-d6) : d 8.1 1 (d, J=2.7 Hz, 1H), 7.37
(d, J=8.7 Hz, 1H), 7.03 (dd, J = 2.7, 8.7 Hz, 1H), 3.36 (brs, 2H), 1.74 (s, 6H); MS (m/z): 162
(M+l) +.
METHOD FOR PREPARATION OF SALTS
Method A: General method for preparation of Mesylate salts
A solution of compound of formula (I) (0.106 mmol) in dry dichloromethane (5 mL) was
stirred at 0 °C. Methane sulfonic acid (0.01021g, 0.106 mmol) dissolved in dry
dichloromethane ( 1 mL) was added drop-wise to the solution of the compound over a period
of 0.5 hours. Reaction mixture was stirred at same temperature for 0.5 hours, warmed to RT
room temperature, and stirred further for 4 hours. Solvent was removed and the mesylate salt
of the compound of formula (I) was obtained. The salt so obtained was characterized by
NMR.
Method B: General method for preparation of Hydrochloride salts
A solution of compound of formula (I) (0.106 mmol) in dry dichloromethane (5 mL) was
stirred at 0 °C. Ethereal HCl was added in excess to the solution of the compound. Reaction
mixture was stirred at same temperature for 0.5 hours, warmed to RT and further stirred for 4
hours. Solvent was removed and the hydrochloride salt of the compound of formula (I) was
obtained. The salt so obtained was characterized by NMR.
EXAMPLES
Example 1: 2-Methyl-2-(5-(3-methyl-2-oxo-8-(pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)propanenitrile
Step 1: 2-(5-(6-Bromo-3-nitroquinolin-4-ylamino)pyridin-2-yl)-2-
methylpropanenitrile
6-bromo-4-chloro-3-nitroquinoline (Intermediate 1, 5.2 mmol) and 2-(5-aminopyridin-2-yl)-
2-methylpropanenitrile (Intermediate 2, 5.2 mmol) were dissolved in acetic acid (5 mL) and
the mixture was stirred overnight. Water was added and the yellow precipitate was filtered
off. The precipitate was washed with water and dried. The solid obtained was partitioned and
extracted with EtOAc and THF, washed with saturated aqueous NaHC . The organic layer
was dried over anhydrous sodium sulfate and concentrated to obtain the title compound. H
NMR (300 MHz, DMSO-d 6) : d 10.17 (s, 1H), 9.12 (s, 1H), 8.73 (s, 1H), 8.44 (s, 1H), 8.06 (d,
J = 10.2 Hz, 1H), 7.97 (d, J = 8.7 Hz, 1H), 7.53 (s, 2H), 1.70 (s, 6H); MS (m/z): 412.0 (M-l)Step 2 : 2-(5-(3-Amino-6-bromoquinolin-4-ylamino)pyridin-2-yl)-2-
methylpropanenitrile
2-(5-(6-bromo-3-nitroquinolin-4-ylamino)pyridin-2-yl)-2-methylpropanenitrile (compound of
step 1, 13.3 mmol) was reduced using Raney-Ni ( 1 g) in THF-MeOH [(1 :1), 50 mL] under 40
psi of hydrogen for 4 hours at RT. After completion of the reaction, the reaction mixture was
filtered and washed with methanol. The filtrate was concentrated and purified (silica gel
column, MeOH/ CHC1 as eluent) to obtain the title compound. H NMR (300 MHz, DMSOd6)
: d 8.63 (s, 1H), 8.19 (s, 1H), 8.04 (d, J = 2.4, 1H), 7.89 (d, J = 2.4, 1H), 7.80 (d, J = 8.7
Hz, 1H), 7.49 (dd, J = 2.1, 8.7 Hz, 1H), 7.33 (d, J = 8.7 Hz, 1H), 6.67 (dd, J = 2.7, 8.4 Hz,
1H), 5.59 (s, 2H), 1.64 (s, 6H); MS (m/z): 384 (M+l) +.
Step 3: 2-(5-(8-Bromo-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-l-yl)pyridin-2-
yl)-2-methylpropanenitrile
A solution of 2-(5-(3-amino-6-bromoquinolin-4-ylamino)pyridin-2-yl)-2-
methylpropanenitrile (compound of step 2, 3.48 mmol) and triethylamine (15.7 mmol) in
DCM(25 mL) was added to a solution of triphosgene (4.17 mmol) in DCM(25 mL) for about
40 minutes at 0 °C. The reaction mixture was stirred for 30 minutes and then quenched with
saturated aqueous NaHC , stirred for 5 minutes and extracted with DCM. The organic layer
was dried over Na2S0 4, filtered and solvent was evaporated to obtain the title compound. H
NMR (DMSO-d 6; 300 MHz): d 11.97 (s, 1H), 8.90 (s, 1H), 8.83 (s, 1H), 8.31-8.23 (m, 1H),
7.98-7.95 (m, 2H), 7.69 (d, J = 9.0 Hz, 1H), 6.99 (s, 1H), 1.8 (s, 6H); MS (m/z): 408 (M+l) +.
Step 4 : 2-(5-(8-Bromo-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-lyl)
pyridin-2-yl)-2-methylpropanenitrile
To a solution of 2-(5-(8-bromo-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-l-yl)pyridin-2-
yl)-2-methylpropanenitrile (compound of step 3, 0.674 mmol) in 5 mL of dry DMF at 0 °C
was added NaH (60 % dispersed in mineral oil, 1.482 mmol). The reaction mixture was
stirred for 15 minutes followed by addition of methyl iodide (0.741 mmol). Reaction mixture
was stirred at 0 °C for another 1 hour and quenched with water. The solvent was removed;
aqueous layer was extracted with DCM. Organic layer was dried over anhydrous Na2S0 4,
concentrated under vacuum and purified (silica gel column, MeOH/CHCb as eluent) to
obtain the title compound. H NMR (300 MHz, DMSO-d 6) : d 9.09 (s, 1H), 8.91 (d, J = 2.4
Hz, 1H), 8.25 (dd, J = 2.4, 8.4 Hz, 1H), 8.02-7.96 (m, 2H), 7.70 (dd, J = 2.1, 9.3 Hz, 1H),
6.99 (d, J = 1.8 Hz, 1H), 3.61 (s, 3H), 1.83 (s, 6H); MS (m/z): 422.1 (M+l) +.
Step 5 : 2-Methyl-2-(5-(3-methyl-2-oxo-8-(pyridin-3-yl)-2,3-dihydro- lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)propanenitrile
Pyridin-3-ylboronic acid (1.233 mmol) and palladium dichlorobis triphenylphosphine (10
mol %) were added to a solution of 2-(5-(8-bromo-3-methyl-2-oxo-2,3-dihydro-lHimidazo[
4,5-c]quinolin-l-yl)pyridin-2-yl)-2-methylpropanenitrile (compound of step 4, 1.1 18
mmol) in dry DMF (3 mL) in an inert atmosphere. Saturated Na2C03 (0.3 mL) was added to
the reaction mixture and the resulting solution was heated at 110 °C for 3 hours. The solvent
was removed; the crude material was extracted in EtOAc, washed with brine and dried over
anhydrous Na2S0 4. The solvent was evaporated and the crude solid was purified (silica gel
column, EtOAc/MeOH as eluent) to obtain the title compound. H NMR (300 MHz, DMSOd6)
: d 8.9 (s, IH), 8.86 (d, J=2.1 Hz, IH), 8.65 (s, IH), 8.60 (d, J = 4.2 Hz, IH), 8.28 (d , J =
9Hz, IH ), 8.02 (dd, J = 2.4 , 8.4 Hz, IH), 7.93 (d, J = 8.4 Hz, IH), 7.86 (dd, J = 8.7, 2.4 Hz,
IH), 7.68-7.66 (m, IH), 7.65 (dd, J = 4.8, 7.8Hz, IH), 7.26 (d, J = 1.8 Hz, IH), 3.75 (s, 3H),
1.90 (s, 6H) ; MS (m/z): 421(M+1) +.
The compounds of Example 2 and 3 were prepared by following the procedure as
described for Example 1, using the compound of step 4, and an appropriate boronic acid
derivative.
Example 2 : 2-Methyl-2-(5-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)propanenitrile
H NMR (300 MHz, CDC1 ) : 8.93 (d, J =2.1 Hz, IH), 8.91 (s, IH), 8.37 (d, J = 8.7 Hz, IH),
8.16 (s, IH), 8.13 (s, IH), 8.05-7.94 (m, 3H), 7.89 (d, J = 7.5Hz, 2H), 7.77-7.71 (m, IH),
7.67-7.60 (m, IH), 7.41 (d, J =1.8 Hz, 1 H), 3.76 (s, 3H), 1.87 (s, 6H); MS (m/z): 471.1
(M+l) +.
Example 3: 2-(5-(8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-
1H-imidazo[4,5-c]quinolin- 1-yl)pyridin-2-yl)-2-methylpropanenitrile
H NMR (300 MHz, DMSO-d 6) : d 9.03 (s, IH), 8.95(d, J= 2.1 Hz, IH), 8.31 (d, J=2.4 Hz,
IH), 8.28 (s, IH), 8.13 (d, J=9.0 Hz, IH), 7.96-7.91 (m, 2H), 7.66 (d, J=1.5 Hz, IH), 7.09 (d,
J=1.2 Hz, IH), 6.71 (s, 2H), 3.62 (s, 3H), 1.81 (s, 6H); MS (m/z): 504.1(M+1) +.
Example 3a: 8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)- 1-(6-(2-cyanopropan-2-yl)pyridin-
3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-5-ium methanesulfonate
The title compound was prepared by following the General method for preparation of
mesylate salts as described in method A, using compound of Example 3. H NMR (300 MHz,
DMSO-de): d 9.37 (s, IH), 8.98 (d, J = 2.4 Hz, IH), 8.34 (m, IH), 8.28 (brs, IH), 8.23 (brs,
2H), 8.00 (d, J= 8.4 Hz, IH), 7.71 (s, IH), 7.18 (s, IH), 6.90 (brs, IH), 3.67 (s, 3H), 2.33
(s,3H), 1.82 (s, 6H); MS (m/z): 504.1(M+1) +.
Example 3b: 8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-l-(6-(2-cyanopropan-2-yl)pyridin-
3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-5-ium chloride
The title compound was prepared by following the General method for preparation of
hydrochloride salts as described in method B, using compound of Example 3. H NMR (300
MHz, DMSO-de): d 9.50 (s, 1H), 9.00(d, J= 2.1 Hz, 1H), 8.46 (d, J=9.0 Hz, 1H), 8.37-8.33
(m, 2H), 8.30 (s, 1H), 8.03 (d,J = 8.7Hz, 1H), 7.74 (bs, 1H), 7.20 (bs, 1H), 7.10-6.80 (bp,
2H), 3.68 (s, 3H), 1.81 (s, 6H); MS (m/z): 504.1(M+1) +.
The compounds of Examples 4-13 were prepared by following the procedure as
described for Example 1, using an appropriate boronic acid derivative.
Ex. No. Nomenclature NMR/Mass
4 2-Methyl-2-(5-(3-methyl- 'H NMR (300 MHz, DMSO-d 6) : d 7.28(d, J =1.8
2-oxo-8-(5- Hz, 1H), 3.64(s, 3H),1.81 (s, 6H);
(trifluoromethy l)pyridin- 3- MS (m/z): 489.2(M+1) +
yl)-2,3-dihydro-lHimidazo[
4,5-c]quinolin- 1-
yl)pyridin-2-yl)
propanenitrile
5 2-Methyl-2-(5-(3-methyl- 'H NMR (300 MHz, DMSO-d 6) : d 9.07 (s, 1H),
2-oxo-8-(quinolin-6-yl)- 9.00 (d, J=2.4 Hz, 1H), 8.90 (bd, J=3.0 Hz, 1H),
2,3-dihydro-lH- 8.40-8.32 (m, 2H), 8.21 (d, J = 9.0 Hz, 1H),
imidazo[4,5-c]quinolin- 1- 8.12-7.98 (m, 4H), 7.62-7.55 (m, 2H), 7.29 (s,
yl)pyridin-2-yl) 1H), 3.64 (s, 3H), 1.82 (s, 6H); MS (m/z):
propanenitrile 471(M+1) +.
6 2-(5-(8-(Isoquinolin-4-yl)- 'H NMR (300 MHz, DMSO-d 6) : d 9.31 (s, 1H),
3-methyl-2-oxo-2,3- 9.13 (s, 1H), 8.91 (s, 1H), 8.34-8.19 (m, 4H),
dihydro-lH-imidazo[4,5- 8.24 (s, 1H), 7.85-7.791 (m, 5H), 7.06 (s, 1H),
c]quinolin- 1-yl)pyridin-2- 3.65 (s, 3H), 1.46 (s, 6H); MS (m/z): 471
yl)-2-methylpropanenitrile (M+l) +.
6a 8-(Isoquinolin-4-yl)- l-(6- NMR (300 MHz, DMSO-d 6) : d 9.34 (s, 1H),
(2-cyanopropan-2- 9.03 (d, J=1.8 Hz, 1H), 8.87 (s, 1H), 8.48 (s,
yl)pyridin-3-yl)-3-methyl- 1H), 8.37 (dd, J=2.1, 8.4Hz, 1H), 8.32 (s, 2H),
2-oxo-2,3-dihydro-lH- 8.08-8.02 (m, 3H), 7.81 (m, 1H), 7.70 (m, 1H),
imidazo[4,5-c]quinolin-5- 7.36 (s, 1H), 3.68 (s, 3H), 2.32 (s, 3H), 1.81 (s,
ium methanesulfonate 6H)
6b 8-(Isoquinolin-4-yl)- l-(6- 'HNMR (300 MHz, DMSO-de): d 9.58 (s, 1H),
(2-cyanopropan-2- 9.05 (d, J = 2.1 Hz, 1H), 8.99 (d, J = 1.8Hz, 1H),
yl)pyridin-3-yl)-3-methyl- 8.62 (m, 2H), 8.51 (m, 1H), 8.40 (dd J = 2.4, 8.4
2-oxo-2,3-dihydro-lH- Hz, 1H), 8.17-8.07 (m, 3H), 7.91 (m, 1H), 7.76
imidazo[4,5-c]quinolin-5- (m, 1H), 7.45 (s, 1H), 3.71 (s, 3H), 1.81 (s, 6H);
ium chloride MS (m/z): 529.2(M+1) +

Ex. No. Nomenclature NMR/Mass
13 2-(5-(8-(2,4- NMR (300 MHz, DMSO-d 6) : d 9.05 (s, IH),
Dimethoxypyrimidin- 5-yl) - 8.92 (d, J=2.1, IH), 8.23 (m, 2H), 8.09 (d, J=
3-methyl-2-oxo-2,3- 8.7Hz, IH), 7.95 (d, J = 8.4Hz, IH), 7.78 (dd, J=
dihydro-lH-imidazo[4,5- 1.8, 9.0 Hz, IH), 7.17 (d, J = 1.5 Hz, IH), 3.90
c]quinolin- 1-yl)pyridin-2- (s, 3H), 3.84 (s, 3H), 3.62 (s, 3H), 1.79 (s, 6H);
yl)-2-methylpropanenitrile MS (m/z): 482.2 (M+l) +.
Example 14: 2-(5-(3-(Cyanomethyl)-2-oxo-8-(pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)-2-methylpropanenitrile
The title compound was prepared by following the procedure as described for Example 1,
except that methyl iodide of step 4 was replaced by 2-bromoacetonitrile. H NMR (300 MHz,
DMSO-de): d 9.03 (s, IH), 8.89 (s, IH), 8.65 (br s, 2H), 8.32 (d, J=8.7 Hz, IH), 8.04 (dd,
J=1.8, 8.4 Hz, IH), 7.97-7.90 (m, 2H), 7.66 (d, J=7.5 Hz, IH), 7.39-7.38 (m, IH), 7.23 (s,
IH), 5.12 (s, 2H), 1.91 (s, 6H); MS (m/z): 446.2 (M+l) +.
Example 15: l-(6-(Dimethylamino)pyridin-3-yl)-3-methyl-8-(pyridin-3-yl)-lH-imidazo[4,5-
c]quinolin-2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that N ,N -dimethylpyridine-2,5-diamine (commercially available, 5.5 mmol) was
used instead of 2-(5-aminopyridin-2-yl)-2-methylpropanenitrile. H NMR (300 MHz,
DMSO-de): d 9.021 (s,lH) , 8.636 (s, IH) , 8.57 (d, J=4.8Hz, IH), 8.324 (s, IH) , 8.14 (d,
J=8.7Hz, IH) , 7.95 (d, J=8.7Hz, IH) , 7.85 (d, J=8.1Hz, IH), 7.78 (d, J=9Hz, IH), 7.456 (s,
IH), 7.429 (s, IH), 6.92 (d, J=9.3Hz, IH), 3.611 (s, 3H), 3.158 (s, 6H); MS (m/z): 397.2
(M+l) +.
Example 16: 2-(5-(8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-(cyanomethyl)-2-oxo-2,3-
dihydro-lH-imidazo[4,5-c]quinolin-l-yl)pyridin-2-yl)-2-methylpropanenitrile
The title compound was prepared by following the procedure as described for Example 1,
except that methyl iodide of step 4 was replaced by 2-bromoacetonitrile and pyridin-3-
ylboronic acid of step 5 was replaced by 5-amino-6-(trifluoromethyl)pyridin-3-ylboronic
acid. H NMR (300 MHz, DMSO-d 6) : d 9.17 (s, IH), 9.05 (d, J= 1.5 Hz, IH), 8.34 (dd, J=2.4,
8.7 Hz, IH), 8.27 (d, J=1.8Hz, IH), 8.14 (d, J=9.0 Hz, IH), 8.00-7.96 (m, 2H), 7.66 (d, J=1.8
Hz, 1H), 7.07 (d, J=1.5 Hz, 1H), 6.74 (s, 2H), 5.45 (s, 2H), 1.81 (s, 6H); MS (m/z):
529.2(M+1) +.
Example 17: 2-(5-(3-(Cyanomethyl)-2-oxo-8-(quinolin-3-yl)-2,3-dihydro- lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)-2-methylpropanenitrile
The title compound was prepared by following the procedure as described for Example 1,
except that methyl iodide of step 4 was replaced by 2-bromoacetonitrile and pyridin-3-
ylboronic acid of step 5 was replaced by quinolin-3-ylboronic acid. H NMR (300 MHz,
DMSO-de): d 9.24 (s, 1H), 9.05 (s, 1H), 8.83 (s, 1H), 8.40 (m, 2H), 8.27 (d, J=8.7 Hz, 1H),
8.20 (d, J=8.7 Hz, 1H), 8.03- 8.01 (m, 3H), 7.79 (m, 1H), 7.67 (m, 1H), 7.28 (s, 1H), 5.49 (s,
2H), 1.82 (s, 6H); MS (m/z): 496.2 (M+l) +.
Example 18: 2-(5-(3-Allyl-2-oxo-8-(pyridin-3-yl)-2,3-dihydro- lH-imidazo[4,5-c]quinolin- 1-
yl)pyridin-2-yl)-2-methylpropanenitrile
The title compound was prepared by following the procedure as described for Example 1,
except that methyl iodide of step 4 was replaced by allyl bromide. H NMR (300 MHz,
DMSO-de): d 8.99 (s, 1H), 8.57 (s, 1H), 8.34 (dd, J = 3.9, 8.4 Hz, 1H), 8.22-8.15 (m, 2H),
8.02-7.98 (m, 2H), 7.78 (d, J = 8.1 Hz, 1H), 7.53 (dd, J = 4.8, 7.8 Hz, 1H), 7.42 (dd, J = 4.8,
7.8 Hz, 1H), 7.14 (d, J = 1.8 Hz, 1H), 6.09-6.03 (m, 1H), 5.37-5.28 (m, 2H), 4.79 (d, J = 5.1
Hz, 2H), 1.84 (s, 6H); MS (m/z): 447.2 (M+l) +.
Example 19: 8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)- 1-(6-methoxypyridin-3-yl)-3-
methyl-lH-imidazo[4,5-c]quinolin-2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that 6-methoxypyridin-3 -amine (commercially available, 5.5 mmol) was used instead
of 2-(5-aminopyridin-2-yl)-2-methylpropanenitrile and pyridin-3 -ylboronic acid of step 4
was replaced by 5-amino-6-(trifluoromethyl)pyridin-3-ylboronic acid. H NMR (300 MHz,
DMSO-de): d 8.98 (s, 1H), 8.51 (d, J=3 Hz, 1H), 8.38 (s, 1H), 8.10 (m, 2H), 7.96 (m, 1H),
7.60 (d, J=3 Hz, 1H), 7.18 (m, 2H), 6.75 (s, 2H), 3.98 (s, 3H), 3.60 (s, 3H); MS (m/z):
467.2(M+1) +.
Example 19a: 8-(6-Ammonio-5-(trifluoromethyl)pyridin-3-yl)- 1-(6-methoxypyridin-3-yl)-3-
methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-5-ium methanesulfonate
The title compound was prepared by following the General method for preparation of
mesylate salts as described in method A, using compound of Example 19. H NMR (300
MHz, DMSO-de): d 9.43 (s, 1H), 8.58 (d, J=3 Hz, 1H), 8.41 (s, 1H), 8.37 (d, J=9 Hz, 1H),
8.27 (d, J=9 Hz, 1H), 8.12 (d, J=9 Hz 1H), 7.65 (s, 1H), 7.31 (s, 1H), 7.22 (d, J=9 Hz, 1H),
3.99 (s, 3H), 3.67 (s, 3H), 2.36 (s, 6H).
Example 20: l-(6-Methoxypyridin-3-yl)-3-methyl-8-(quinolin-3-yl)-lH-imidazo[4,5-
c]quinolin-2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that 6-methoxypyridin-3 -amine (commercially available, 5.5 mmol) was used instead
of 2-(5-aminopyridin-2-yl)-2-methylpropanenitrile and pyridin-3-ylboronic acid of step 5 was
replaced by quinolin-3-ylboronic acid. H NMR (300 MHz, DMSO-d 6) : d 9.06 (s, 1H), 8.92
(d, J=3 Hz, 1H), 8.56 (d, J=3 Hz, 1H), 8.42 (s, 1H), 8.23 (d, J=9 Hz, 1H), 8.15-8.09 (m, 2H),
8.08 (d, J=9 Hz, 1H), 7.99 (d, J=9 Hz, 1H), 7.83-7.77 (m, 1H), 7.71-7.66 (m, 1H) 7.47 (s, 1H)
7.24 (d, J= 9Hz, 1H), 4.01 (s, 3H), 3.63 (s, 3H); MS (m/z): 434 (M+l) +.
Example 2 1: 2-(l-(6-Methoxypyridin-3-yl)-2-oxo-8-(pyridin-3-yl)-lH-imidazo[4,5-
c]quinolin-3(2H)-yl)acetonitrile
The title compound was prepared by following the procedure as described for Example 1,
except that 6-methoxypyridin-3 -amine (commercially available, 5.5 mmol) was used instead
of 2-(5-aminopyridin-2-yl)-2-methylpropanenitrile and methyl iodide of step 4 was replaced
by 2-bromoacetonitrile. H NMR (300 MHz, DMSO-d 6) : d 9.21 (s, 1H), 8.61-8.58 (m, 3H),
8.22 (d, J=9 Hz, 1H), 8.13 (dd, J = 2.7, 8.7 Hz, 1H), 8.02 (dd, J = 1.8, 8.7 Hz, 1H), 7.89-7.86
(m, 1H), 7.50 (dd, J= 4.8, 7.8 Hz, 1H), 7.31 (d, J = 1.5 Hz, 1H), 7.20 (d, J=9 Hz, 1H), 5.45 (s,
2H), 4.00 (s, 3H); MS (m/z): 409 (M+l) +
.
The compounds of Examples 22-29 were prepared by following the procedure as
described for Example 19, using methyl iodide or 2-bromoacetonitrile and an appropriate
boronic acid derivative.

The compounds of Examples 30-35 were prepared by following the procedure as
described for Example 19, using 6-ethoxypyridin-3-amine instead of 6-methoxypyridin-3-
amine and an appropriate boronic acid derivative.
Ex. Nomenclature NMR/Mass
No.
30 8-(6-Amino-5- 'HNMR (300 MHz, DMSO-de): d 9.00 (s, IH), 8.10-
(trifluoromethyl) pyridin- 7.94 (m, 3H), 7.58-7.57 (d, IH, J=3Hz), 7.18-7.17 (d,
3-yl)- 1-(6-ethoxypyridin-3- IH, J=3Hz), 7.12-7.09 (d, IH, J=9Hz), 6.75 (s, 2H),
yl)-3 -methyl- 1H- 4.45- 4.38 (q, 2H, J=9Hz, J=6Hz, J=6Hz), 3.61 (s,
imidazo [4,5 -c]quinolin- 3H), 1.41-1.37 (t, 3H, J=6Hz, J=6Hz); MS
2(3H)-one (m/z):481.2 (M+l) +.
3 1 8-(6-(Dimethylamino) 'HNMR (300 MHz, DMSO-de): d 8.97(s, IH), 8.15-
pyridin-3-yl)-l-(6- 8.14 (d, J=3.0 Hz, IH), 8.08-8.01 (m, 3H), 7.89-7.85
ethoxypyridin-3 -yl)-3 - (dd, J=3Hz, J=9 Hz, IH), 7.58-7.53 (m, 2H), 7.15-
methyl- 1H-imidazo [4,5- 7.12 (m, 3H), 6.67-6.64 (m, 2H), 4.53-4.43 (m, 2H),
c]quinolin-2(3H)-one 3.6 (s, 3H), 3.63 (s, 3H), 3.07 (s, 6H), 1.44-1.39 (t,
3H, J=6Hz); MS (m/z): 441(M+1) +.
32 1-(6-Ethoxypyridin-3-yl)- 'HNMR (300 MHz, DMSO-de): d 9.10 (s, IH), 8.94-
3-methyl-8-(quinolin-3-yl)- 8.93 (d, J=3.0Hz, IH), 8.54-8.53 (d, IH, J=3Hz),
1H-imidazo [4,5- 8.24-8.14 (m, 3H), 8.1 1-8.08 (m, 2H), 7.98-7.95 (d,
c]quinolin-2(3H)-one J=9 Hz, IH), 7.83-7.77 (t, IH, J=9Hz), 7.71-7.68 (t,
IH, J=9Hz), 7.44 (s, IH), 7.20-7.17 (d, J=9Hz), 4.48-
4.42 (q, 2H, J=3Hz, J=9Hz), 3.63 (s, 3H), 1.41-1.36
(t, 3H, J=6Hz); MS (m/z): 448.2 (M+l) +.
33 8-(2,6-Difluoropyridin-3- 'HNMR (300MHZ , DMSO-de): d 9.07 (s, IH), 8.44
yl)- 1-(6-ethoxypyridin-3- (d, J=2.4Hz, IH), 8.27 (m, IH), 8.26 (d, J=9Hz, IH),
yl)-3 -methyl- 1H- 8.01 (dd, J=9Hz, 2.7Hz, IH), 7.84 (d, J=9Hz, IH),
imidazo [4,5 -c]quinolin- 7.38 (s, IH), 7.32 (dd, J=8.1Hz, 2.7Hz, IH), 7.08 (d,
2(3H)-one J=8.7Hz, IH), 4.44 (m, 2H), 3.61 (s, 3H), 1.40 (t,
J=7.2Hz, 3H); MS (m/z): 434 (M+l) +.
Ex. Nomenclature NMR/Mass
No.
34 1-(6-Ethoxypyridin-3-yl)- H NMR (300 MHz, DMSO-d 6) : d 9.03 (s, 1H), 8.64
8-(2-methoxypyrimidin- 5- (s, 2H), 8.49 (d, J=1.8Hz, 1H), 8.16 (d, J=9Hz, 1H),
yl)-3 -methyl- 1H- 8.05 (dd, J=8.7Hz, 1.8Hz, 1H), 7.96 (dd, J=8.7Hz,
imidazo [4,5 -c]quinolin- 1.5Hz, 1H), 7.24 (d, J=1.8Hz, 1H), 7.14 (d, J=8.7Hz,
2(3H)-one 1H), 4.48 (m, 2H), 3.95 (s, 3H), 3.61 (s, 3H), 1.42 (t,
J=7.2Hz, 3H); MS (m/z): 429(M+1) +.
35 1-(6-Ethoxypyridin-3-yl)- 'HNMR (300MHZ , DMSO-d 6) : d 9.04 (s, 1H), 8.93
3-methyl-8-(quinolin-6-yl)- (d, J=2.7Hz, 1H), 8.54 (d, J=2.7Hz, 1H), 8.34 (d,
lH-imidazo[4,5- J=8.4Hz, 1H), 8.20 (d, J=8.7Hz, 1H), 8.02 (m, 4H),
c]quinolin-2(3H)-one 7.78 (d, J=9Hz, 1H), 7.63 (m, 1H), 7.40 (s, 1H), 7.20
(d, J=8.7Hz, 1H), 4.38 (m, 2H), 3.62 (s, 3H), 1.41 (t,
J=6.9Hz, 3H); MS (m/z): 448(M+1) +.
The compounds of Examples 36-41 were prepared by following the procedure as
described for Example 19, using 6-methoxy-2-methylpyridin-3-amine instead of 6-
methoxypyridin-3 -amine, methyl iodide or 2-bromoacetonitrile and an appropriate boronic
acid derivative.
Ex. No. Nomenclature NMR/Mass
36 2-(l-(6-Methoxy-2- 'HNMR (300 MHz, DMSO-de): d 9.23 (s, 1H), 8.91-
methylpyridin-3 -yl)-2- 7.90 (d, 1H, J=3Hz), 8.39 (s, 1H), 8.24-8.20 (m, 2H),
oxo-8-(quinolin-3-yl)- 8.09-8.06 (m, 2H), 7.99-7.96 (d, 1H, J=9Hz), 7.81
lH-imidazo[4,5- (m, 1H), 7.69 (m, 1H), 7.34 (s, 1H), 7.07-7.04 (d,
c]quinolin-3(2H)-yl) 1H, J=9Hz), 5.49 (s, 2H), 3.99 (s, 3H), 2.26 (s, 3H);
acetonitrile MS (m/z):473(M+l) +.
37 2-(l-(6-Methoxy-2- 'HNMR (300 MHz, DMSO-de): d 9.04 (s, 1H), 8.74
methylpyridin-3 -yl)-2- (s, 1H), 8.35-8.32 (d, 1H, J=9Hz), 7.90-7.82 (m, 2H),
oxo-8-(6- 7.76-7.73 (d, 1H, J=9Hz), 7.65-7.62 (d, 1H, J=9Hz),
(trifluoromethyl)pyridin 7.35 (s, 1H), 6.89-6.86 (d, 1H, J=9Hz), 5.19-4.94 (m,
-3-yl)-lH-imidazo[4,5- 2H), 4.07 (s, 3H), 2.33 (s, 3H); MS (m/z):
c]quinolin-3(2H)-yl) 491(M+1) +.
acetonitrile
38 8-(6-Amino-5- 'HNMR (300 MHz, DMSO-de): d 9.01 (s, 1H), 8.36
(trifluoromethyl)pyridin (s, 1H), 8.11-8.08 (d, 1H, J=9Hz), 7.98-7.92 (m, 2H),
-3-yl)- 1-(6-methoxy-2- 7.58 (s, 1H), 7.07 (s, 1H), 6.97-6.94 (d, 1H, J=9Hz),
methylpyridin-3 -yl)-3 - 6.76 (s, 2H), 3.96 (s, 3H), 3.62 (s, 3H), 2.20 (s, 3H);
methyl- 1H- MS (m/z): 505 (M+l) +.
imidazo [4,5-c]quinolin-
2(3H)-one
Example 42: 5-(3-(Cyanomethyl)-2-oxo-8-(pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]
quinolin- 1-yl)picolinonitrile
The title compound was prepared by following the procedure as described for Example 1,
except that 5-aminopicolinonitrile (commercially available, 5.5 mmol) was used instead of 2-
(5-aminopyridin-2-yl)-2-methylpropanenitrile and methyl iodide of step 4 was replaced by 2-
bromoacetonitrile. H NMR (300 MHz, DMSO-d6) : d 9.24 (s, 1H), 9.19 (d, J=3 Hz, 1H),
8.65 (d, J=3 Hz, 1H), 8.58 (dd, J= 1.2, 4.5 Hz, 1H), 8.54 (dd, J=2.4, 8.4 Hz, 1H), 8.47 (d, J =
8.4 Hz, 1H), 8.25 (d, J=9 Hz, 1H), 8.03 (dd, J = 1.8, 9.6 Hz, 1H), 7.90-7.87 (m, 1H), 7.48
(dd, J = 4.8, 7.8 Hz, 1H), 7.28 (d, J = 1.5 Hz, 1H), 5.48 (s, 2H); MS (m/z): 404 (M+l) +.
Example 43: 5-(3-(l-Cyanoethyl)-2-oxo-8-(pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)picolinonitrile
The title compound was prepared by following the procedure as described for Example 1,
except that 5-aminopicolinonitrile (commercially available, 5.5 mmol) was used instead of 2-
(5-aminopyridin-2-yl)-2-methylpropanenitrile and methyl iodide of step 4 was replaced by 2-
bromopropanenitrile. H NMR (300 MHz, DMSO-d6) : d 9.18 (s, 1H), 8.68 (s, 1H), 8.63 (d,
J=3 Hz, 1H), 8.56-8.52 (m, 1H), 8.47 (d, J=9 Hz, 1H) 8.27 (d, J=9 Hz, 1H), 8.15-8.02 (m,
1H), 7.98 (d, J=3 Hz, 1H), 7.56 (m, 1H), 7.13 (s, 1H), 6.96 (s, 1H), 6.17 (m, 1H), 1.90 (d, J =
7.2 Hz, 3H); MS (m/z): 418 (M+l) +.
Example 44: 5-(3-Methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-lyl)
picolinonitrile
The title compound was prepared by following the procedure as described for Example 1,
except that 5-aminopicolinonitrile (commercially available, 5.5 mmol) was used instead of 2-
(5-aminopyridin-2-yl)-2-methylpropanenitrile and pyridin-3-ylboronic acid of step 5 was
replaced by quinolin-3-ylboronic acid. H NMR (300 MHz, DMSO-d6) : d 9.01 (d, J=2.1 Hz,
1H), 8.96 (s, 1H), 8.90 (s, 1H), 8.32 (d, J=8.7 Hz, 1H), 8.12-8.22 (m, 3H), 7.98-8.05 (m, 2H),
7.90 (d, J=8.1 Hz, 1H), 7.76-7.81 (m, 1H), 7.63-7.68 (m, 1H), 7.45 (d, J=1.2 Hz, 1H), 3.73 (s,
3H); MS (m/z): 429 (M+l) +.
Example 45: 5-(8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydrolH-
imidazo[4,5-c]quinolin-l-yl)picolinonitrile
The title compound was prepared by following the procedure as described for Example 1,
except that 5-aminopicolinonitrile (commercially available, 5.5 mmol) was used instead of 2-
(5-aminopyridin-2-yl)-2-methylpropanenitrile and pyridin-3-ylboronic acid of step 5 was
replaced by 6-amino-5-(trifluoromethyl)pyridin-3-ylboronic acid. H NMR (300 MHz,
DMSO-de): d 9.14-9.13 (d, 1H, J=3Hz), 9.04 (s, 1H), 8.49-8.39 (m, 3H), 8.13-8.10 (d, 1H,
J=9Hz), 8.00-7.97 (m, 1H), 7.62 (s, 1H), 7.14 (s, 1H), 6.77 (s, 2H), 3.62 (s, 3H), MS (m/z):
461.9 (M+l) +.
The compounds of Examples 46-50 were prepared by following the procedure as
described for Example 44, using an appropriate boronic acid derivative.
Ex. No. Nomenclature NMR/Mass
46 5-(8-(2-Fluoropyridin-3- 'HNMR (300 MHz, DMSO-de): d 9.12 (s, 1H), 9.10-
yl)-3-methyl-2-oxo-2,3- 9.1 1 (d, 1H, J=1.8 Hz), 8.39-8.49 (m, 2H), 8.18-8.25
dihydro- lH-imidazo[4,5- (m, 2H), 8.06-8.1 1 (m, 1H), 7.87-7.90 (d, 1H, J= 9
c]quinolin-l-yl) Hz), 7.45-7.49 (m, 1H), 7.36 (s, 1H), 3.63 (s, 3H);
picolinonitrile MS (m/z): 397(M+1) +.
Ex. No. Nomenclature NMR/Mass
47 5-(8-(6-Fluoropyridin-3- HNMR (300 MHZ , DMSO-d 6) : d 9.1 1-9.12 (d, 1H,
yl)-3-methyl-2-oxo-2,3- J=1.5 Hz), 9.10 (s, 1H), 8.40-8.46 (m, 2H), 8.31 (s,
dihydro- lH-imidazo[4,5- 1H), 8.18-8.21 (d, 1H, J=9 Hz), 8.08-8.09 (m, 1H),
c]quinolin-l-yl) 7.95-7.98 (d, 1H, J= 8.7Hz), 7.28-7.30 (m, 2H), 3.63
picolinonitrile (s, 3H); MS (m/z): 397 (M+l) +.
48 5-(8-(6-Methoxypyridin- 'HNMR (300 MHz, DMSO-de): d 9.13 (s, 1H), 9.07
3-yl)-3-methyl-2-oxo-2,3- (s, 1H), 8.45 (s, 2H), 8.26 (s, 1H), 8.15-8.18 (d, 1H,
dihydro- lH-imidazo[4,5- J=9 Hz), 7.91-7.94 (d, 1H, J=8.1 Hz), 7.77-7.80 (d, 1H,
c]quinolin-l- J= 7.8 Hz ), 7.21 (s, 1H), 6.89-6.92 (d, 1H, J=7.8 Hz),
yl)picolinonitrile 3.89 (s, 3H), 3.63 (s, 3H); MS (m/z): 409 (M+l) +.
49 5-(3-Methyl-2-oxo-8- HNMR (300 MHz, DMSO-d 6) : d 9.06-9.14 (m, 2H),
(pyridin-3 -yl)-2,3 - 8.65 (s, 1H), 8.58-8.59 (d, 1H, J=4.2 Hz), 8.43-8.49
dihydro- lH-imidazo[4,5- (m, 2H), 8.19-8.22 (d, 1H, J=9 Hz), 7.97-8.00 (d, 1H,
c]quinolin-l-yl) J=9 Hz), 7.88-7.90 (d, 1H, J= 8.1 Hz ), 7.47-7.51 (dd,
picolinonitrile 1H, J=4.5, 7.5 Hz), 7.30 (s, 1H), 3.64 (s, 3H);
MS (m/z): 379 (M+l) +.
50 5-(8-(6- 'HNMR (300 MHz, DMSO-de): d 9.12-9.09 (d, J=9Hz,
(Dimethylamino)pyridin- 1H), 8.49-8.42 (m, 2H), 8.15-8.13 (d, J=6 Hz, 2H),
3-yl)-3-methyl-2-oxo-2,3- 7.95-7.92 (d, J=3Hz, 1H), 7.64-7.51 (m, 2H), 7.16 (s,
dihydro- lH-imidazo[4,5- 1H), 6.81 (s, 1H), 3.62 (s, 3H), 3.10 (s, 6H);
c]quinolin-l- MS (m/z): 422 (M+l) +
yl)picolinonitrile
The following compound was prepared by the procedure as described for Example 42,
using an appropriate boronic acid derivative.
Example 51: 5-(3-(Cyanomethyl)-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)picolinonitrile
HNMR (300 MHz, DMSO-de): d 9.25 (s, 1H), 9.22 (d, 1H, J=2.1 Hz), 8.96 (d, 1H, J=2.4
Hz), 8.57 (d, 1H, J=2.4 Hz), 8.52 (s, 1H), 8.46 (d, 1H, J= 2.1 Hz), 8.22 (m, 2H), 8.06 (m,
2H), 7.77 (m, 2H), 7.43 (d, 1H, J= 1.5 Hz), 5.49 (s, 2H); MS (m/z): 454 (M+l) +.
The following compound was prepared by the procedure as described for Example 43, using
an appropriate boronic acid derivative.
Example 52: 5-(3-(l-Cyanoethyl)-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)picolinonitrile
'HNMR (300 MHz, DMSO-de): d 9.30 (s, 1H), 9.22-9.23 (d, 1H, J=2.1 Hz), 8.98-8.99 (d, 1H,
J=2.4 Hz), 8.60-8.64 (dd, 1H, J=3, 9 Hz), 8.49-8.58 (m, 2H), 8.21-8.33 (m, 2H), 8.01-8.13
(m, 2H), 7.79-7.94 (m, 2H), 7.43-7.44 (d, 1H, J=1.2 Hz), 3.43 (s, 3H);
MS (m/z): 468 (M+l) +.
Example 53: 3-Methyl- 8-(pyridin-3-yl)- 1-(6-(trifluoromethyl)pyridin-3-yl)- lH-imidazo[4,5-
c]quinolin-2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that 6-(trifluoromethyl)pyridin-3-amine (commercially available, 5.5 mmol) was used
instead of 2-(5-aminopyridin-2-yl)-2-methylpropanenitrile. H NMR (300 MHz, DMSO-d 6) :
d 9.17 (d, J=1.8 Hz, 1H), 9.10 (s, 1H), 8.61 (d, J=1.8 Hz, 1H), 8.57-8.54 (m, 1H), 8.52 (d, J =
1.8 Hz, 1H), 8.34 (d, J = 8.1 Hz, 1H), 8.21 (d, J=8.7 Hz, 1H), 7.99 (dd, J = 2.1, 9.0 Hz, 1H),
7.82-7.79 (m, 1H), 7.42 (dd, J=4.8, 7.89 Hz, 1H), 7.18 (d, J = 1.8 Hz, 1H), 3.64 (s, 3H); MS
(m/z): 422.1 (M+l) +.
Example 54: 3-Methyl-8-(quinolin-3-yl)-l-(6-(trifluoromethyl)pyridin-3-yl)-lH-imidazo[4,5-
c]quinolin-2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that 6-(trifluoromethyl)pyridin-3 -amine (commercially available, 5.5 mmol) was used
instead of 2-(5-aminopyridin-2-yl)-2-methylpropanenitrile and pyridin-3-ylboronic acid of
step 5 was replaced by quinolin-3-ylboronic acid. H NMR (300 MHz, DMSO-d 6) : d 9.21 (d,
J=3 Hz, 1H), 9.12 (s, 1H), 8.97 (d, J=3 Hz, 1H), 8.55-8.56 (m, 1H), 8.39 (s, 1H), 8.36-8.35
(m, 1H), 8.23 (d, J=9 Hz, 1H), 8.17-8.16 (m, 1H), 8.06 (d, J=9 Hz, 1H), 7.95 (d, J=9 Hz,
1H), 7.79-7.80 (m, 1H), 7.69-7.67 (m, 1H), 7.38 (d, J=3 Hz, 1H), 3.66 (s, 3H); MS (m/z):
472 (M+l) +.
Example 55: 8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-methyl-l-(6-(trifluoromethyl)
pyridin-3-yl)- lH-imidazo[4,5-c]quinolin-2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that 6-(trifluoromethyl)pyridin-3 -amine (commercially available, 5.5 mmol) was used
instead of 2-(5-aminopyridin-2-yl)-2-methylpropanenitrile and pyridin-3-ylboronic acid of
step 5 was replaced by 6-amino-5-(trifluoromethyl)pyridin-3-ylboronic acid. H NMR (300
MHz, DMSO-de): d 9.15 (s, IH), 9.08 (s, IH), 8.54-8.51 (d, IH, J=9Hz), 8.42 (s, IH), 8.30-
8.27 (d, IH, J=9Hz), 8.15-8.12 (d, IH, J=9Hz), 8.01-7.98 (d, IH, J=3H), 7.57 (s, IH), 7.1 1 (s,
IH), 6.75 (s, 2H), 3.63 (s, 3H); MS (m/z): 505 (M+l) +.
Example 55a: 8-(6-Ammonio-5-(trifluoromethyl)pyridin-3-yl)-3-methyl-2-oxo- 1-(6-
(trifluoromethyl)pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-5-ium
methanesulfonate
The title compound was prepared by following the General method for preparation of
mesylate salts as described in method A. H NMR (300 MHz, DMSO-d6) : d 9.46 (s, IH),
9.18 (s, IH), 8.60 (d, J=9 Hz, IH), 8.46 (s, IH), 8.36 (m, 3H), 7.63 (s, IH), 7.24 (s, IH), 3.69
(s, 3H), 2.37 (s, 6H).
The compounds of Examples 56 and 57 were prepared by following the procedure as
described for Example 53, using the appropriate boronic acid derivative.
The compound of Example 58 was prepared by following the procedure as described
for Example 53, using 2-chloro-6-(trifluoromethyl)pyridin-3-amine instead of 6-
methoxypyridin-3 -amine and an appropriate boronic acid derivative.
Example 58: 6-Chloro-5-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)picolinonitrile
H NMR (300 MHz, DMSO-d 6) : d 9.14 (s, 1H), 8.93 (s, 1H), 8.85 (d, J=7.8 Hz, 1H), 8.48 (d,
J=8.1 Hz, 1H), 8.34 (s, 1H), 8.27 (d, J = 8.7 Hz, 1H), 8.17 (d, J=9 Hz, 1H), 8.06 (d, J=8.1 Hz,
1H), 7.95 (d, J= 8.1Hz, 1H), 7.79 (t, J=7.2 Hz, 1H), 7.67 (t, J=7.2 Hz), 3.67 (s, 3H); MS
(m/z): 506 (M+l) +.
Example 59: 8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)- 1-(2-chloro-6-(trifluoromethyl)
pyridin-3-yl)-3-methyl-lH-imidazo[4,5-c]quinolin-2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that 2-chloro-6-(trifluoromethyl)pyridin-3-amine (commercially available, 5.5 mmol)
was used instead of 2-(5-aminopyridin-2-yl)-2-methylpropanenitrile and pyridin-3-ylboronic
acid of step 5 was replaced by 6-amino-5-(trifluoromethyl)pyridin-3-ylboronic acid. H NMR
(300 MHz, DMSO-de): d 9.07 (s, 1H), 8.79 (d, J = 8.1 Hz, 1H), 8.39 (d, J = 9.0 Hz, 2H), 8.14
(d, J = 9.0 Hz, 1H), 8.00 (d, J = 10.5 Hz, 1H), 7.54 (s, 1H), 6.93 (s, 1H), 6.75 (s, 2H), 3.65 (s,
3H); MS (m/z): 539(M+l) +.
Example 60: l-(6-Chloropyridin-3-yl)-3-methyl-8-(pyridin-3-yl)-lH-imidazo[4,5-c]quinolin-
2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that 6-chloropyridin-3-amine (commercially available, 5.5 mmol) was used instead of
2-(5-aminopyridin-2-yl)-2-methylpropanenitrile. H NMR (300 MHz, DMSO-de): d 9.08 (s,
1H), 8.81 (d, J=2.1 Hz, 1H), 8.62-8.57 (m, 2H), 8.28 (dd, J = 3.0, 8.7 Hz, 1H), 8.20 (d, J = 8.7
Hz, 1H), 7.98-7.86 ( m, 3H), 7.50-7.48 (m, 1H), 7.27 (s, 1H), 3.64 (s, 3H); MS (m/z): 388.1
(M+l) +.
Example 61: l-(6-Chloropyridin-3-yl)-3-methyl-8-(quinolin-3-yl)-lH-imidazo[4,5-
c]quinolin-2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that 6-chloropyridin-3-amine (commercially available, 5.5 mmol) was used instead of
2-(5-aminopyridin-2-yl)-2-methylpropanenitrile and pyridin-3-ylboronic acid of step 5 was
replaced by quinolin-3-ylboronic acid. H NMR (300 MHz, DMSO-d6) : d 9.09 (s, 1H), 8.97
(d, J= 1.8 Hz, 1H), 8.85 (d, J= 2.1 Hz, 1H), 8.42 (s, 1H), 8.33 (dd, J=2.4, 8.4 Hz, 1H), 8.24
(d J=9 Hz, 1H), 8.15 (d J=9 Hz, 1H), 8.03-7.97 (m, 2H), 7.94 (m, 1H), 7.83-7.78 (m, 1H),
7.72-7.67 (m, 1H), 7.47 (s, 1H), 3.63 (s, 3H); MS (m/z): 438.1(M+1) +.
Example 62: l-(2,6-Dichloropyridin-3-yl)-3-methyl-8-(pyridin-3-yl)- lH-imidazo[4,5-
c]quinolin-2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that 2,6-dichloropyridin-3-amine (commercially available, 5.5 mmol) was used instead
of 2-(5-aminopyridin-2-yl)-2-methylpropanenitrile. H NMR (300 MHz, DMSO-d 6) : d 9.41
(d, J=1.8 Hz, 1H), 9.10 (s, 1H), 8.77 (d, J=3.6 Hz, 1H), 8.61-8-53 (m, 3H), 8.03 (d , J=9 Hz,
1H), 7.73 (dd, J=2.1, 9 Hz, 1H), 7.75 (dd, J=4.8, 8.1 Hz, 1H), 7.10 (d, J=3.9 Hz, 1H), 3.65 (s,
3H); MS (m/z): 467.9 [M+2Na]+.
Example 63: l-(6-Chloro-2-(trifluoromethyl)pyridin-3-yl)-3-methyl-8-(pyridin-3-yl)-lHimidazo[
4,5-c]quinolin-2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that 2-chloro-6-(trifluoromethyl)pyridin-3-amine (commercially available, 5.5 mmol)
was used instead of 2-(5-aminopyridin-2-yl)-2-methylpropanenitrile. H NMR (300 MHz,
DMSO-de): d 9.13 (s, 1H), 8.79 (d, J= 7.8 Hz, IH), 8.57 (d, J=6 Hz, 2H), 8.43 (d, J=8.1 Hz,
1H), 8.20 (d, J = 9 Hz, 1H), 8.00 (dd, J=.8, 9 Hz, 1H), 7.79 (d, J=8.1 Hz, 1H), 7.43 (dd, J=4.8,
7.8 Hz, 1H), 7.01 (d, J=0.9 Hz, 1H), 3.67 (s, 3H); MS (m/z): 455.9 [M]+.
Example 64: l-(6-(Dimethylamino)pyridin-3-yl)-3-methyl-8-(quinolin-3-yl)-lH-imidazo[4,5-
c]quinolin-2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that N2,N2-dimethylpyridine-2,5-diamine (commercially available, 5.5 mmol) was
used instead of 2-(5-aminopyridin-2-yl)-2-methylpropanenitrile and pyridin-3-ylboronic acid
of step 5 was replaced by quinolin-3-ylboronic acid. H NMR (300 MHz, DMSO-de): d 9.051
(s, 2H), 8.87 (m, 1H), 8.34 (m, 2H), 8.16 (d J=ll.lHz 2H), 7.98 (d, J=8.4Hz, 1H), 7.84 (d,
J=7.8Hz, 1H), 7.76 (m, 1H), 7.58 (m, 2H), 6.73 (d, J=9Hz, 1H), 3.268 (s, 6H), 3.736 (s, 1H);
MS (m/z): 447(M+H)
Example 65: 3-Methyl-8-(quinolin-3-yl)-l-(quinolin-6-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-
one
The title compound was prepared by following the procedure as described for Example 1,
except that quinolin-6-amine (commercially available, 5.5 mmol) was used instead of 2-(5-
aminopyridin-2-yl)-2-methylpropanenitrile and pyridin-3-ylboronic acid of step 5 was
replaced by quinolin-3-ylboronic acid. 'HNMR (300 MHz, DMSO-d6) : d 9.14 (s, 1H), 9.07
(m, 1H), 8.46-8.43 (m, 2H), 8.19-7.49 (m, 11H), 6.83 (s, 1H), 3.70 (s, 3H);
MS (m/z): 454 (M+l) +.
Example 66: 3-Methyl-l-(quinolin-6-yl)-8-(5-(trifluoromethyl)pyridin-3-yl)-lH-imidazo[4,5-
c]quinolin-2(3H)-one
The title compound was prepared by following the procedure as described for Example 65,
except that quinolin-3-ylboronic acid was replaced by 5-(trifluoromethyl)pyridin-3-ylboronic
acid. H NMR (300 MHz, DMSO-d6) : d 9.16 (s, 1H), 9.03 (d, J=2.7 Hz, 1H), 8.87 (s, 1H),
8.56 (s, 1H), 8.41-8.31 (m, 2H), 8.17-7.98 (m, 5H), 7.61 (s, 1H), 7.52 (dd, J = 4.2 , 8.7 Hz,
1H), 6.76 (s, 1H), 3.69 (s, 3H); MS (m/z): 472 (M+l) +.
Example 67: 8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-methyl-l-(quinolin-6-yl)-lHimidazo[
4,5-c]quinolin-2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that quinolin-6-amine (commercially available, 5.5 mmol) was used instead of 2-(5-
aminopyridin-2-yl)-2-methylpropanenitrile and pyridin-3-ylboronic acid of step 5 was
replaced by replaced by 6-amino-5-(trifluoromethyl)pyridin-3-ylboronic acid. H NMR (300
MHz, DMSO-de): d 9.07 (s, 1H), 9.02 (d, J=7.8 Hz, 1H), 8.37 (d, J= 7.8 Hz, 1H), 8.1 1 (m,
4H), 7.85 (d, J=7.5 Hz, 2H), 7.53 (q, J= 4.2 Hz, 1H), 7.26 (s, 1H), 6.70 (s, 2H), 6.57 (s, 1H),
3.67 (s, 3H); MS (m/z): 487(M+1) +.
Example 68: 3-Methyl-l-(2-morpholinoethyl)-8-(pyridin-3-yl)-lH-imidazo[4,5-c]quinolin-
2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that 2-morpholinoethanamine (commercially available, 5.5 mmol) was used instead of
2-(5-aminopyridin-2-yl)-2-methylpropanenitrile. H NMR (300 MHz, DMSO-d6) : d 9.15 (d,
J = 2.1 Hz, 1H), 8.94 (s, 1H), 8.65 (dd, = 1.2, 4.5 Hz, 1H), 8.53 (d, J = 1.5 Hz, 1H), 8.3 1
(m, 1H), 8.17 (d, J =9 Hz, 1H), 8.37 (dd, J = 1.5, 9 Hz, 1H), 7.58 (dd, J = 4.5, 7.8 Hz, 1H),
4.56 (t, J = 6.9 Hz, 2H), 3.56 (s, 3H), 3.49 (t, J = 4.2 Hz, 4H), 2.72 (t, J = 6.6 Hz, 2H), 2.24
(m, 4H); MS (m/z): 390 (M+l) +.
Example 69: 8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-methyl- l-(2-morpholinoethyl)-
lH-imidazo[4,5-c]quinolin-2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that 2-morpholinoethanamine (commercially available, 5.5 mmol) was used instead of
2-(5-aminopyridin-2-yl)-2-methylpropanenitrile and pyridin-3-ylboronic acid of step 5 was
replaced by 6-amino-5-(trifluoromethyl)pyridin-3-ylboronic acid. H NMR (300 MHz,
DMSO-de): d 8.89 (s, 1H), 8.76 (s, 1H), 8.36 (s, 1H), 8.22 (s, 1H), 8.09 (d, J = 9 Hz, 1H),
7.97 (d, J = 8.7 Hz, 1H), 6.74 (s, 2H), 4.55 (m, 3H), 3.54 (s, 3H), 3.50 (m, 4H), 2.72 (m, 3H),
2.49 (m, 2H); MS (m/z): 473.2 (M+l) +.
Example 70: 3-Methyl- l-(2-morpholinoethyl)-8-(quinolin-3-yl)- lH-imidazo[4,5-c]quinolin-
2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that 2-morpholinoethanamine (commercially available, 5.5 mmol) was used instead of
2-(5-aminopyridin-2-yl)-2-methylpropanenitrile and pyridin-3-ylboronic acid of step 5 was
replaced by quinolin-3-ylboronic acid. H NMR (300 MHz, DMSO-d6) : d 9.50 (d, J= 2.1 Hz,
1H), 8.95 (s, 1H), 8.87 (d, J = 1.8 Hz, 1H), 8.66 (s, 1H), 8.24-8.08 (m, 4H), 7.84 -7.79 (m,
1H), 7.72-7.67 (m, 1H), 4.60-4.58 (m, 2H), 3.57 (s, 3H), 3.46-3.40 (m, 4H), 2.74 (m, 2H),
2.38 (m, 4H); MS (m/z): 440 (M+l).
Example 71: 3-Methyl- l-(6-(4-methylpiperazin- l-yl)pyridin-3-yl)-8-(pyridin-3-yl)- lHimidazo[
4,5-c]quinolin-2(3H)-one
Compound of example 60 (0.0 10 g, 0.026 mmol) and 1-methyl piperazine ( 1 mL, 9.02 mmol)
were subjected to microwave irradiation for 30 minutes at 130 °C. Crude product was
purified (silica gel column, MeOH/ CHCI3 as eluent) to obtain the title compound. H NMR
(300 MHz, DMSO-de): d 10.21 (s, 1H), 9.07 (s, 1H), 8.59 (s, 1H), 8.46 (d, J = 2.4 Hz, 1H),
8.18 (d, J=8.7 Hz, 1H), 8.02-7.91 (m, 3H), 7.54-7.49 (m, 1H), 7.41 (d, J = 1.5 Hz, 1H), 7.28
(d, J=9 Hz, 1H), 4.61-4.56 (m, 2H), 3.62 (s, 3H), 3.16-3.02 (m, 6H), 2.90 (s, 3H); MS (m/z):
452 (M+l) +.
Example 72: l-(6-Chloro-2,4'-bipyridin-3-yl)-3-methyl-8-(pyridin-3-yl)-lH-imidazo[4,5-
c]quinolin-2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that 6-chloro-2,4'-bipyridin-3 -amine (commercially available, 5.5 mmol) was used
instead of 2-(5-aminopyridin-2-yl)-2-methylpropanenitrile. 'HNMR (300 MHz, DMSO-d 6) : d
9.41 (d, J=1.8 Hz, 1H), 9.1 (s, 1H), 8.77 (d, J=3.6 Hz, 1H), 8.61 (m, 2H), 8.03 (d , J=9 Hz,
1H), 7.73 (dd, J=2.1, 9 Hz, 1H), 7.75 (dd, J=4.8, 8.1 Hz, 1H), 7.10 (d, J=3.9 Hz, 1H), 3.65 (s,
3H); MS (m/z): 467.9 [M+2Na]+.
Example 73: 3-Methyl-l-(6-morpholinopyridin-3-yl)-8-(quinolin-3-yl)-lH-imidazo[4,5-
c]quinolin-2(3H)-one
A compound of Example 6 1 (0.022 g, 0.050 mmol) and morpholine (2 mL) were subjected to
microwave irradiation for 20 minutes at 129°C in microwave vessel. After completion, the
reaction was quenched in water and extracted using chloroform. The crude product was
further purified by silica gel column chromatography using MeOH/ CHCI 3 as eluent to obtain
the title compound. H NMR (300 MHz, DMSO-d 6) : d 9.02 (s, 1H), 8.93 (s, 1H), 8.45 (m,
2H), 8.27(s, 1H), 8.21(d, J=9 Hz, 1H), 8.09 (d, J=9Hz, 1H), 7.91 (d, J=9Hz, 1H), 7.85 (m,
1H),7.76( S, 1H) , 7.66(m,3H) 3.91 (m, 4H), 3.72 (m, 4H), 3.70 (s, 3H); MS m/z 489 (M+l) +.
Example 74: 8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-methyl-l-(2-(trifluoromethyl)
pyrimidin-5-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that 2-(trifluoromethyl)pyrimidin-5-amine (commercially available, 5.5 mmol) was
used instead of 2-(5-aminopyridin-2-yl)-2-methylpropanenitrile and pyridin-3-ylboronic acid
of step 5 was replaced by 5-amino-6-(trifluoromethyl)pyridin-3-ylboronic acid. H NMR
(300 MHz, DMSO-de): d 9.49 (s, 2H), 9.07 (s,lH), 8.50 (d, J=5.4 Hz, 1H), 8.16 (d, J=8.7 Hz,
1H), 8.02 (dd, J=8.7, 1.5 Hz, 1H), 7.72 (s, 1H), 7.36 (s, 1H), 6.73 (s, 2H), 3.64 (s, 3H); MS
(m/z): 506 (M+l)
Example 75: 8-(5-Amino-6-methoxypyridin-3-yl)-l-(6-methoxypyridin-3-yl)-3-methyl-lHimidazo[
4,5-c]quinolin-2(3H)-one
The title compound was prepared by following the procedure as described for Example 1,
except that 6-methoxypyridin-3 -amine (commercially available, 5.5 mmol) was used instead
of 2-(5-aminopyridin-2-yl)-2-methylpropanenitrile and pyridin-3-ylboronic acid of step 5
was replaced by 5-amino-6-methoxypyridin-3-ylboronic acid. ¾ NMR: (300HZ, DMSO de):
d 8.96 (s, 1H), 8.47-8.46 (d, 1H, J=3Hz), 8.08-8.00 (m, 2H), 7.74-7.71 (d, 1H, J=9Hz), 7.32-
7.31 (d, 1H, J=3Hz), 7.19-7.16 (m, 2H), 6.92-6.91 (d, 1H, J=3Hz), 5.06 (d, 2H), 3.96 (s, 3H),
3.86 (s, 3H), 3.57 (s, 1H); MS (m/z): 429(m+l).
TESTING OF COMPOUNDS
The efficacy of the present compounds can be determined by a number of
pharmacological assays well known in the art, such as described below. The exemplified
pharmacological assays, which follow herein, have been carried out with the compounds of
the present invention.
Example 76: Protocol for kinase assay (PI3Ka)
p 110a radioactive lipid kinase assay
The assay was designed as in the reference, Journal of Biomolecular Screening, 2002,
Vol. 7, No. 5, 441-450, the disclosure of which is incorporated herein by reference for the
teaching of the assay.
The p 110a biochemical assay was performed using a radioactive assay measuring the
incorporation of P into the p i 10a substrate, phosphatidylinsoitol (PI). For the generation of
IC50 curves, the reaction was performed in a 96-well MaxiSorp plates. Plates were pre-coated
with 4 mg/well of a 1:1 ratio of phosphatidylinositol (PI: Avanti #840042C) and
phosphatidylserine (PS: Avanti #840032C) diluted in CHCI3. Equal amount of p i 10a
(Upstate Millipore) protein was added to each well, containing 25 mΐ reaction buffer (50 mM
MOPSO pH7.0, 100 mM NaCl, 4 mM MgCl2, 0.1% (w/v) BSA) whereas, for negative
control, only reaction buffer was added. Compounds of the present invention dissolved in
DMSO were treated at nine-point dose responses (0.3, 1, 3, 6, 10, 30, 60, 100 and 300nM).
Reactions were initiated by the addition of 25 mM ATP solution (Sigma, USA) containing 50
m / [g - R]-ATR and incubated at RT for 2 hours with gentle shaking. Reactions were
finally terminated by the addition of 100 mΐ of 50 mM EDTA stock solution. Plates were
washed 3 times with TBS buffer. The plates were air dried, Microscint 0 (Perkin Elmer) was
added to each well and the plates were sealed. The radioactivity incorporated into the
immobilized PI substrate was determined with Top Count (Perkin Elmer). Inhibition was
calculated using the following equation:
% inhibition = (Dcpm - Tcpm)/(Dcpm) X 100.
Tcpm = P-cpm in presence of compounds of the present invention
Dcpm = P-cpm in DMSO control (enzyme control deducted)
IC50 values for compounds of Example 19 and Example 3a are 2.886 nM and 1.368 nM
respectively.
Example 77: mTOR inhibition assay
The compounds of the present invention were tested at ProQinase, Germany. Compound of
Example 3a inhibited mTOR enzyme activity with IC50 value of 4.4 nM.
Example 78: Protocol for ALKl and ALK2 inhibition assay
The in vitro kinase assays using recombinant human, catalytic domain of ALKl
(ACVRLl) or ALK2 (ACVR1) kinase GST fusion proteins (Invitrogen, USA) were
conducted using a time-resolved fluorescence (TR-FRET) format. Kinase reactions were
carried out in a 384-well plate format in a final volume of 20 mΐ . The standard enzyme
reaction buffer consisted of 50 mM Tris HCL (pH: 7.4), 1mM EGTA, 10 mM MgCl2, 2 mM
DTT, 0.01% Tween-20, 20 nM of ALKl / ALK2 kinase enzyme (Invitrogen, USA), 50 nM
of peptide substrate (DNA Topoisomerase 2 alpha (Thr 1342)U1 peptide, Perkin Elmer, USA)
and 20 mM of ATP. Various concentrations of compound of Example 3a in DMSO (final
concentration 2%), was added to give a final concentration of the compound ranging from 20
mM to 20 pM. [20 nM of enzyme and compound in various concentrations were pre
incubated for 10 minutes at 23 °C followed by the addition of 50 nM of the peptide substrate].
Reaction was initiated with the addition of 20 mM of ATP. After incubation for 1 hour at 23
°C, kinase reaction was stopped with the addition of 5 mΐ EDTA (final concentration of 10
mM in 20 mΐ) . Eu donor [Eu cryptate -anti-phospho-Topoisomerase 2-alpha (Thr 1342),
Perkin Elmer, USA] at a final concentration of 2 nM was added and the mixture was allowed
to equilibrate for lhour at 23 °C. After irradiation of the kinase reaction at 320 or 340 nm,
the energy from the Eu donor was transferred to its acceptor which, in turn, generates light at
665 nm. The intensity of the light emission is proportional to the level of the substrate
phosphorylation. The IC50 values for compound of Example 3a were determined by a fourparameter
sigmoidal curve fit (Sigma plot or Graph pad). IC50 value for compound of
Example 3a for ALK-1 is 42 nM and for ALK-2 is 47 nM.
Example 79: Protocol for Western Blot Analysis
A2780 ovarian cancer cell line (ATCC) were grown to approximately 70%
confluence in 100-mm tissue culture dishes and then treated for 1 hour with 50 mΐ - 100 mΐ
compounds of Example 2, 3, 5, 16, 19, 55 and 59. Total protein was extracted using cell
lysis buffer (NaCl 200 nM, NP40 0.67%, Tris-Cl, pH 7.5, 67 mM) containing protease
inhibitors and phosphatase inhibitors (Beta-glycerol phosphate 40 mM, DTT ImM, NaF 0.4
mM, Sodium-Orthovanadate 0.4 mM) at 4°C for 1 hour. Cell lysates were then centrifuged at
2 x 104 g for 10 minutes at 4°C, and the protein concentration of the supernatant was
quantified using the Bradford's method (BioRad, USA). For SDS-PAGE, 50 mg protein was
loaded in SDS-PAGE, transferred to a polyvinylidene difluoride membrane (Bio-Rad, USA)
and blocked with 5mL buffer [5% skim milk and 0.1% Tween] for 1 hour 30 minutes.
Membrane were probed with primary antibody (all primary antibodies were from cell
signaling with 1:1000 in TBST solution) of respective protein at 4 °C overnight. Peroxidaselabeled
anti-rabbit or anti-mouse antibodies (Santacruze, USA) were used as the secondary
antibody. Actin and respective whole protein levels were used as the control for protein
loading. Protein antigens were detected using Chemiluminescent Substrate (Thermo
scientific, USA) and exposed on Kodak station. The results (FIG. 1A-1E) demonstrate that
compounds of Example 2, 3, 5, 16, 19, 55, 59 and Example 3a inhibit Akt, S6 and 4EBP1
phosphorylation and hence are inhibitors of PI3K/mTOR pathway.
Example 80: Cytotoxicity assay
Propidium Iodide Assay
The assay was designed as in the reference, Anticancer Drugs, 2002, 13, 1-8, the
disclosure of which is incorporated herein by reference for the teaching of the assay.
Cells from cell lines (ATCC) as mentioned in the table given below were seeded at a
density of 3000 cells/well in a white opaque 96-well plate. Following incubation at 37 °C/ 5
% CO2 for a period of 18-24 hours, the cells were treated with various concentrations (stock
solution was prepared in DMSO and subsequent dilutions were made in media as per ATCC
guidelines) of the compounds of the present invention for a period of 48 hours. At the end of
treatment, the culture medium was discarded, the cells were washed with 1 x PBS and 200
mΐ of 7 mg/mL propidium iodide was added to each well. The plates were frozen at -70 °C
overnight. For analysis, the plates were warmed to RT, allowed to thaw and were read in
PoleStar fluorimeter with the fluorescence setting. The percentage of viable cells in the nontreated
set of wells was considered to be 100 and the percentage viability following treatment
was calculated accordingly. IC50 values were calculated from graphs plotted using these
percentages. IC50 values for certain compounds of present invention are depicted in Table 1
and % Inhibition of certain compounds of present invention are depicted in Table 2.
The Cell Lines as used in the above assay are:
Type of Cancer Abbreviation Cell Line Abbreviation
Ovarian CI A2780 Cla
Prostate C2 PC3 C2a
Breast C3 MDA MB 231 C3a
MDA MB 468 C3b
BT 549 C3c
MCF7 C3d
Pancreatic C4 PANC 1 C4a
AsPC 1 C4b
BxPC3 C4c
Glioblastoma C5 LN229 C5a
LN18 C5b
U 87 MG C5c
C6 K562 C6a
Chronic Myeloid T315I C6b
Leukemia (CML) KU812/SR C6c
KU812 C6d
KCL22/SR C6e
KCL22 C6f
Table 1: IC 0 Values in mM
Cmpds. of 20 38 49 53 54 55 59 60
Example No.®
Cell Lines
CI Cla 0.07 <0.005 0.009 0.55 0.16 0.009 <0.01 0.68
C2 C2a 0.27 0.0078 0.017 0.75 0.55 1.6 0.018 0.85
C3 C3a 0.37 — 0.016 ~ 0.55 0.035 <0.01 ~
C3b 0.47 -- 0.065 ~ 1.2 0.075 0.07 ~
C3c 1 — 0.3 ~ 1 0.17 0.04 ~
C3d 0.55 -- 0.03 ~ 0.8 0.06 0.013 ~
C4 C4a 0.25 — 0.035 ~ 0.95 ~ 0.017 ~
C4b 0.4 — 0.025 ~ 0.55 0.04 0.042 ~
C4c 0.45 — 0.04 ~ 0.78 0.027 <0.01 ~
C5 C5a ~ — ~ ~ — 0.096 ~ ~
C5b ~ — ~ ~ — 0.282 ~ ~
C5c ~ -- ~ ~ -- 7.92 ~ ~
C6 C6a 0.1 — ~ ~ — 0.056 ~ ~
C6b 1.96 — ~ ~ — 0.19 ~ ~
C6c 5.44 -- ~ ~ -- 0.23 ~ ~
C6d 1.99 -- ~ ~ -- ~ ~
C6e 1.09 — ~ ~ — 0.06 ~ ~
C6f 2.86 — ~ ~ — ~ ~
Cmpds. of 62 63 67 68 69 70 72
Example No. ®
Cell Lines
CI Cla ~ ~ 0.006 1.4 0.022 0.3 5
C2 C2a ~ ~ 0.015 2.4 0.07 0.9 ~
C3 C3a ~ ~ 0.012 2.3 — 0.7 ~
C3b ~ ~ 0.05 7 — 1.1 ~
C3c 1.5 5.6 0.01 1 >10 — 2.1
11
n
C3d ~ 4 0.02 3 -- 0.7
C4 C4a ~ ~ 0.025 4.6 — 1 ~
C4b ~ ~ 0.035 4.6 — 1.6 ~
C4c ~ ~ 0.0085 2.4 -- 0.7 ~
C5 C5a 1.032 ~ ~ ~ — ~ 0.44
C5b 1.08 ~ ~ ~ — ~ 0.992
C5c 9.92 ~ ~ ~ — ~ ~
C6 C6a 0.144 0.224 ~ ~ — 0.7 0.0144
C6b ~ ~ ~ ~ -- 2.56 ~
C6c 0.84 ~ ~ ~ — 3.38 1.14 20
C6d ~ ~ ~ ~ — 4 ~
C6e 0.62 ~ ~ ~ -- 1.57 0.23
C6f ~ ~ ~ ~ — 2.17 ~
Table 2 : % Inhibition at 1 mM
The symbol - indicates that the compounds were not tested.
Example 81: Protocol for Tube Formation Assay
Cell Culture: Human umbilical vein endothelial cells (HUVECs) (ATCC) used in passages 2-
7. The cells were grown in endothelial medium (Promocell, Germany) supplemented with
20% fetal bovine serum (FBS), 100 units/mL penicillin, 100 mg/mL streptomycin, 3 ng/mL
basic fibroblast growth factor, and 5 units/mL heparin at 37°C under a humidified 95% (v/v)
mixture of air and CO2.
Tube Formation Assay: 250 mΐ of growth factor-reduced Matrigel (BD Biosciences) was
pipetted into a 24 well tissue culture plate and polymerized for 30 minutes at 37°C. HUVECs
incubated in endothelial media containing 1% FBS for 6 hours were harvested after trypsin
treatment and suspended in endothelial media containing 1% FBS. Compounds of present
invention (75 nM) were added to the cells for 30 minutes at RT before seeding and plated
onto the layer of Matrigel at a density of 2 xlO4 cells/well, and followed by the addition of 2
mL of 40 ng/mL VEGF. After 18 hours, the cultures were photographed.
Results: When HUVECs were placed on growth factor-reduced Matrigel in the presence of
VEGF, VEGF led to the formation of elongated and robust tube-like structures, which were
organized by much larger number of cells compared with the control. FIG. 2 demonstrates
that compound of Example 3a effectively abrogated the width and the length of endothelial
tubes induced by VEGF.
Example 82: Protocol for In-vivo assay
Animals: Severe combined immunodeficient (SCID) mice (Male and Female) 6 to 8 weeks
old, were used. Animals were housed in suitable cages under specified pathogen-free
conditions in rooms maintained at 23 °C and 50% humidity, with a 12- hour light/12- hour
dark cycle. The mice were quarantined during the acclimatization period of at least a week.
Tumor growth inhibition studies in vivo
Prostate cancer xenograft model: PC3 (human prostate cancer) cell line (ATCC) was
maintained in RPMI 1640 (Gibco BRL, Pasley, UK) supplemented with 10 % (v/v) FBS. The
cells were incubated at 37 °C in a humidified atmosphere containing 5% CO2. Cells were
passaged using trypsin/EDTA for cell detachment once every 3 days. On the day of tumor
cell injection, cells were detached from the flasks with trypsin/EDTA, washed once in
medium and re-suspended in serum free RPMI 1640 at 5 million cells/0.2 mL volume, and
placed on ice. Severe combined immunodeficient mice were injected with 0.2 mL of the cell
suspension subcutaneously on the right flank and observed daily for tumor appearance.
Procedure: Tumor-bearing mice were randomized (n = 7 per group) in four groups when the
mean tumor volume was 100 mm3. Each group was closely matched before treatment,
which began 2 to 3 weeks after cell transplantation. Twice a week, each xenograft was
measured in two dimensions (a = length; b = width) with a caliper. Tumor volume (V) was
determined by the following equation: V = ab /2
Tumor volumes were converted into tumor weights assuming a tumor density of 1mm3 = 1
mg. Tumor growth inhibition (TGI) for each group was calculated according to the following
formula:
( 1 - [T - To] / [C - Co]) x 100
Wherein, T and To are the mean tumor volumes on a specific experimental day and on day 1
of treatment, respectively, for the experimental groups. Likewise, for the control groups, C
and Co are the mean tumor volumes on a given day and on day 1 of the study, respectively.
Animals in each group were observed every day for signs of health deterioration and animal
weight was recorded daily out to day 28 post tumor transplantation.
Treatment of animals: Tumor bearing animals were randomized in four groups,
i) Group 1: Control group-Tumor-bearing mice were administered with vehicle
ii) Group 2 : Tumor-bearing mice were administered once daily p.o with 3 mg/kg of
compound of Example 3a
iii) Group 3: Tumor-bearing mice were administered twice daily (BID) p.o with 3 mg/kg of
compound of Example 3a
iv) Group 4 : Tumor-bearing mice were administered once daily p.o with 3 mg/kg of the
compound of Example 19 using 1mL tuberculin syringes fitted with feeding needles with
round tip and Luer lock hub.
Compounds of the present invention were formulated in 0.5% carboxymethyl cellulose and
0.1% Tween 80 in water. The application volume was 10 mL/kg. Treatment continued for 15
days.
Results: FIG. 3A shows that the compound of Example 19 and the compound of Example 3a
effectively inhibit tumor growth in-vivo at a concentration of 3 mpk.
Pancreatic Cancer xenograft model: The human pancreatic carcinoma cells, (PANC-1)
(ATCC) were grown in Eagle's Minimum Essential Medium (SAFC, US) supplemented with
10% (v/v) fetal bovine serum. The cells were incubated at 37 °C in a humidified atmosphere
containing 5% CO2. On the day of tumor cell injection, cells were harvested and resuspended
in serum free Eagle's Minimum Essential Medium and BD Matrigel™ (BD Biosciences,
USA) basement membrane matrix (50:50, v/v) at 5 million cells/0.2 mL volume, and placed
on ice. Severe combined immunodeficient mice were injected with 0.2 mL of the cell
suspension subcutaneously on the right flank and observed daily for tumor appearance.
Tumor-bearing mice were randomized in two groups when the mean tumor weight was 100
mg. Each group was closely matched before treatment, which began one week after cell
transplantation. Twice a week, each xenograft was measured in two dimensions (a = length; b
= width) with a caliper. Tumor volume (V) was determined by the following equation:
V= ab /2
Tumor volumes were converted into tumor weights assuming a tumor density of 1mm3 = 1
mg. Tumor growth inhibition (TGI) for each group was calculated according to the following
formula:
(l - [T - T0] / [C - Co]) x lOO
Wherein, T and To are the mean tumor volumes on a specific experimental day and on day 1
of treatment, respectively, for the experimental groups. Likewise, for the control groups, C
and Co are the mean tumor volumes on a given day and on day 1 of the study, respectively.
Animals in each group were observed every day for signs of health deterioration and animal
weight was recorded daily.
Treatment of animals: Tumor bearing animals were randomized in two groups,
i) Group 1: Control group-Tumor-bearing mice were administered with vehicle
ii) Group 2 : Tumor-bearing mice were administered once daily p.o with 3 mg/kg of
compound of Example 3a using 1 mL tuberculin syringes fitted with feeding needles
with round tip and Luer lock hub.
Compounds of the present invention were formulated in 0.5% carboxymethyl cellulose and
0.1% Tween 80 in water. The application volume was 10 mL/kg. Treatment continued for 14
days.
Results: FIG. 3B shows that compound of Example 3a effectively inhibited the growth of
pancreatic tumors in a mouse xenograft model at the concentration of 3 mpk.
Example 83: Con-A-induced IFN-g production from hPBMC
Peripheral blood was collected from normal healthy volunteers after informed consent.
Peripheral blood mononuclear cells (hPBMC) were harvested using Ficoll-Hypaque density
gradient centrifugation (1.077 g/mL; Sigma Aldrich). hPBMCs were resuspended in RPMI
1640 culture medium (Gibco BRL, Pasley, UK) containing 10% FCS, 100 U/mL penicillin
(Sigma Chemical Co. St Louis, MO) and 100 mg/mL streptomycin (Sigma Chemical Co. St
Louis, MO) at lxl 06 cells/mL. lxl 05 hPBMCs/well were pre-treated with 0.025 mM of
compounds of present invention or 0.5% DMSO (vehicle control) for 30 minutes at 37 °C.
Subsequently, these cells were stimulated with 1 mg/mL concanavalin A (Sigma Chemical
Co., St. Louis, MO). Following 18 hours of incubation at 37°C, supematants were collected
and stored at -70 °C until assayed for human IFN-g by ELISA as described by the
manufacturer (OptiEIA ELISA sets, BD Biosciences). In every experiment, cyclosporin ( 1
mM) was used as a positive control for inhibiting induced IFN-g production. In all
experiments, the toxicity of test compounds was ascertained, in parallel, using the MTS (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfonyl)-2H-tetrazolium)
assay as described in Am. J. Physiol. Cell Physiol., 2003, 285, C813-C822.
Example No. % Inhibition of IFN- % Toxicity
g at 0.025 mM at 0.025 mM
2 58 12
3 98 2 1
16 3 1 3
19 93 18
57 88 14
Compounds of the present invention inhibit the proliferation of human T-cells.
Example 84: Anti-CD3 mAb and anti-CD28 mAb-induced cytokine production assay
Preparation of anti-CD3/anti-CD28 coated plates: 96 well plates were coated with goat antimouse
IgG, Fc (Millipore) at a concentration of 16.5 mg/mL in coating buffer (8.4 g/mL
NaHC0 3, 3.56 g Na2C0 , pH 9.5). Following overnight incubation at 4 °C, the plates were
washed and then incubated with anti-CD3 (3.5 mg/mL; R&D Systems) and anti-CD28 (35
ng/mL; R&D Systems) cocktail for 3 hours. Subsequently, the plates were washed, and used
for hPBMC stimulation.
hPBMC stimulation: Peripheral blood was collected from normal healthy volunteers after
informed consent. Peripheral blood mononuclear cells (hPBMC) were harvested using
Ficoll-Hypaque density gradient centrifugation (1.077g/mL; Sigma Aldrich). hPBMCs were
resuspended in RPMI 1640 culture medium (Gibco BRL, Pasley, UK) containing 10% FCS,
100 U/mL penicillin (Sigma Chemical Co. St Louis, MO) and lOOmg/mL streptomycin
(Sigma Chemical Co. St Louis, MO) at 1.25 xlO6 cells/mL of assay medium. 2.5 x 105
hPBMCs were added per well of 96-well plate coated with or without anti-CD3/anti-CD28
mAbs. Simultaneously, 0.025 mM of compounds of the present invention or 0.5% DMSO
(vehicle control) were added to appropriate wells. The cells were then incubated for 18 hours
at 37 °C, 5% CO2 following which supematants were collected, stored at -70 °C and assayed
later for TNF-a, IL-6 and IFN-g by ELISA (OptiEIA ELISA sets; BD Biosciences). In every
experiment, each condition was run in triplicate wells. In all experiments, the toxicity of test
compounds was ascertained, in parallel, using the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfonyl)-2H-tetrazolium) assay as described in Am. J. Physiol.
Cell Physiol., 2003, 285, C813-C822.
Compound % Inhibition of cytokine at 0.025 M % Toxicity
TNF-a IL-6 IFN-g at 0.025mM
2 63 43 7 1 12
3 92 84 93 24
16 8 1 75 80 0
19 87 86 87 19
57 80 94 88 14
Compounds of the present invention inhibit the activation of human T-cells and consequent
production of pro-inflammatory cytokines.
Example 85: Protocol for Collagen-induced arthritis
Induction of collagen-induced arthritis and treatment with compound of Example 19
All animal experiments were carried out in accordance with the guidelines of
Committee for the Purpose of Control and Supervision of Experiments on Animals
(CPCSEA). All animal experiments were approved by Institutional Animal Ethics
Committee (IAEC) of Piramal Life Sciences Limited, Mumbai, India. Collagen-induced
arthritis was induced in DBA/1J mice as described in J. Exp. Med., 1985, 162, 637-46.
Inbred male DBA/1J mice (8-10 weeks of age, Jackson Laboratories, Bar Harbor, Maine)
were immunized intradermally at the base of the tail with 200 mg type II collagen emulsified
in Freund's Complete Adjuvant (FCA) on day 0. On day 17, immunized mice were
randomized into different groups based on their body weight. From day 17 onwards, (i) one
group of mice started receiving administration of compound of Example 19 ( 1 mg/kg, p.o.,
twice daily), (ii) a second group of mice started receiving administration of vehicle (0.5%
CMC, p.o., twice daily), and (iii) a third group of mice started receiving administration of
Enbrel (3 mg/kg, s.c, once daily). On day 21, all mice were boosted with 200 mg type II
collagen emulsified in FCA. The mice (8 per treatment group) were monitored daily (from
day 17 onwards) for the development and severity of arthritis using articular index and paw
thickness as parameters. Articular index scoring was performed employing the following
criteria - Fore limbs (Scale 0-3): 0, no redness or swelling; 1, redness but no swelling; 2,
redness and swelling of the paw; 3, redness and severe swelling of the paw. Hind limbs
(Scale 0-4): 0, no redness or swelling; 1, redness and mild swelling of paw; 2, redness and
moderate swelling of paw and/or swelling of at least one of the digits; 3, redness and
moderate/severe swelling of paw, swelling of ankle joint and/or swelling of one or more
digits; 4, redness and severe swelling of paw, digits and ankle joint, with joint stiffness and
altered angle of digits. The total articular index for a mouse is sum of individual articular
index scores of fore limbs and hind limbs. Swelling of each of the paws of mice was
measured with constant-tension, spring-loaded calipers (Mitutoyo, Aurora, IL). All
measurements and scoring were performed by operators blinded to the treatment groups.
Treatment continued daily until day 36 of the study, and the body weight of the
animal along with the severity of inflammation for all 4 paws was monitored daily. In every
experiment, a group of non-immunized mice was maintained alongside as na'ive control. On
the last day of experiment, one hour after compound of Example 19, vehicle, or Enbrel
administration, the animals were humanely euthanized.
The results as depicted in FIG. 4a and 4b show that the compound of Example 19 (i)
inhibits disease-associated increase in articular index and paw thickness, (ii) distinctly
protects against bone erosion and joint space narrowing, and (iii) prominently diminishes
joint destruction, hyperproliferative pannus formation and infiltration of inflammatory cells.
It should be noted that, as used in this specification and the appended claims, the
singular forms "a", "an", and "the" include plural referents unless the content clearly dictates
otherwise. Thus, for example, reference to a composition containing "a compound" includes
a mixture of two or more compounds. It should also be noted that the term "or" is generally
employed in its sense including "and/or" unless the content clearly dictates otherwise.
All publications and patent applications in this specification are indicative of the level
of ordinary skill in the art to which this invention pertains.
The invention has been described with reference to various specific and preferred
embodiments and techniques. However, it should be understood that many variations and
modifications may be made while remaining within the spirit and scope of the invention.
CLAIMS
What is claimed is:
A compound of formula (I)
formula (I)
wherein,
R is selected from alkylheterocyclyl, alkylheteroaryl or heteroaryl, wherein
each of heterocyclyl and heteroaryl is optionally substituted with one or more groups
selected from R ;
R2 is -C1-C4 alkyl, optionally substituted with one or more groups
independently selected from -CN or -C2-C4 alkenyl;
R3 is selected from heteroaryl or -C6 -C14 aryl, wherein each of aryl and
heteroaryl is optionally substituted with one or more groups selected from R ;
R at each occurrence is independently selected from halogen, -CN, -OR x, -
NRxRy, -NR xCOR , -COORx, -CONR xR , halo-Ci-C 4 alkyl, -C1-C4 alkyl,
heterocyclyl or heteroaryl, wherein each of alkyl, heterocyclyl, and or heteroaryl is
optionally substituted with one or more groups independently selected from -CN or -
C1-C4 alkyl;
R31 at each occurrence is independently selected from halogen, -OR x, -CN, -
NRxRy, -NRxCORy, -COOR x, -CONR xRy, halo-Ci-C 4 alkyl or -C1-C4 alkyl;
wherein Rx and Ry at each occurrence are independently selected from
hydrogen or -C1-C4 alkyl; or
a stereoisomer, a tautomer, a polymorph, a prodrug, an N-oxide, a
pharmaceutically acceptable salt or a solvate thereof.
The compound according to claim 1, wherein R is selected from pyridyl, pyrimidinyl
or quinolinyl, wherein pyridyl, pyrimidinyl and quinolinyl are optionally substituted
with one or more groups independently selected from halogen, -CN, -OR x, -NR xRy,
halo-Ci-C4 alkyl, -C1-C4 alkyl, heterocyclyl or heteroaryl, wherein each of -C1-C4
alkyl, heterocyclyl and heteroaryl is optionally substituted with one or more groups
independently selected from -CN or -C1-C4 alkyl and Rx and Ry at each occurrence are
independently selected from hydrogen or -C1-C4 alkyl.
The compound according to claim 2, wh a substituted pyridyl group
represented by the structural formula wherein, the symbol
indicates the point of attachment to the rest of the molecule; R i is selected from -
CI, -CN, -OCH 3, -OC 2H , -N(CH )2, -CF 3, -C(CH )2CN, morpholinyl or
piperazinylmethyl; and Rn 2 is selected from hydrogen, CI, CH or pyridyl.
The compound according to any one of the preceding claims 1 to 3, wherein R2 is
methyl, optionally substituted with one or more groups independently selected from -
CN or -C2-C4 alkenyl.
The compound according to claim 4, wherein R2 is methyl.
The compound according to any one of the preceding claims 1 to 5, wherein R is
heteroaryl optionally substituted with one or more groups independently selected from
halogen, -OR x, -NR xRy, -Ci-C4-alkyl or halo-Ci-C4-alkyl, wherein Rx and Ry at each
occurrence are independently selected from hydrogen or -C1-C4 alkyl.
The compound according to claim 6, wherein R is selected from pyridyl or
quinolinyl; wherein pyridyl and quinolinyl are optionally substituted with one or
more groups independently selected from halogen, -OR x, NRxRy, -Ci-C4-alkyl or
halo-Ci-C4-alkyl, wherein Rx and Ry at each occurrence are independently selected
from hydrogen or -C1-C4 alkyl.
The compound according to any one of the preceding claims 1 to 7, wherein R is
substituted pyridyl represented by the structural formula , wherein
the symbol indicates the point of attachment to the rest of the molecule; and each of
R31 1, R312 and R is independently selected from hydrogen, halogen, -ORx, -NRxRy, -
Ci-C4-alkyl or halo-Ci-C4-alkyl, wherein Rx and Ry at each occurrence are
independently selected from hydrogen or -C1-C4 alkyl.
The compound according to claim 8, wherein each of R31 1, R312 and R313 is
independently selected from hydrogen, halogen, -O-C 1-C4 alkyl, -N¾, -NH-C 1-C4-
alkyl, -N(Ci-C4-alkyl)2 or methyl; wherein methyl is optionally substituted with one to
three halogen atoms.
The compound according to claim 9, wherein each of R31 1, R312 and R313 is
independently selected from hydrogen, F, -OCH 3, -NH2, -NH-CH3, -N(CH )2 or -
CF .
The compound according to claim 9, wherein R is -N¾ ; R312 and R313 are
independently selected from hydrogen, halogen, -O-C 1-C4 alkyl, -N¾ , -NH-C 1-C4-
alkyl, -N(Ci-C 4-alky1)2 or methyl; wherein methyl is optionally substituted with one
to three halogen atoms.
The compound according to claim 9, wherein R313 is -CF3 and R31 1 and R312 are
independently selected from hydrogen, halogen, -O-C1-C4 alkyl, -NH2, -NH-C1-C4-
alkyl, -N(Ci-C4-alkyl)2 or methyl; wherein methyl is optionally substituted with one to
three halogen atoms.
The compound according to claim 8, wherein R is -NH2 and R313 is -CF 3 and R312 is
selected from hydrogen, halogen, -O-C1-C4 alkyl, -NH2, -NH-Ci-C 4-alkyl, -N(d-C 4-
alkyl)2 or methyl; wherein methyl optionally substituted with one to three halogen
atoms.
The compound according to claim 13, wherein R is -NH2, R is -CF 3 and R 2 IS
hydrogen.
The compound according to claim 1, selected from:
2-Methyl-2-(5-(3-methyl-2-oxo-8-(pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)propanenitrile,
2-Methyl-2-(5-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)propanenitrile,
2-(5-(8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lHimidazo[
4,5-c]quinolin-l-yl)pyridin-2-yl)-2-methylpropanenitrile,
2-Methyl-2-(5-(3-methyl-2-oxo-8-(5-(frifluoromethyl)pyridin-3-yl)-2,3-dihydro-lHimidazo
[4,5-c]quinolin- 1-yl)pyridin-2-yl) propanenitrile,
2-Methyl-2-(5-(3-methyl-2-oxo-8-(quinolin-6-yl)-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl) propanenitrile,
2-(5-(8-(Isoquinolin-4-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-lyl)
pyridin-2-yl)-2-methylpropanenitrile,
2-(5-(8-(2-Hydroxyquinolin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)-2-methylpropanenitrile,
2-(5-(8-(6-(Dimethylamino) pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lHimidazo[
4,5-c]quinolin-l-yl)pyridin-2-yl)-2-methylpropanenitrile,
2-Methyl-2-(5-(3-methyl-2-oxo-8-(pyrimidin-5-yl)-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)propanenitrile,
2-(5-(8-(2,6-Difluoropyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)-2-methylpropanenitrile,
2-(5-(8-(5-Fluoro-2-methoxyphenyl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)-2-methylpropanenitrile,
2-(5-(8-(2-Fluoro-5-(trifluoromethyl) phenyl)-3-methyl-2-oxo-2,3-dihydro-lHimidazo[
4,5-c]quinolin-l-yl)pyridin-2-yl)-2-methylpropanenitrile,
2-(5-(8-(2,4-Dimethoxypyrimidin-5-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)-2-methylpropanenitrile,
2-(5-(3-(Cyanomethyl)-2-oxo-8-(pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)-2-methylpropanenitrile,
1-(6-(Dimethylamino)pyridin-3-yl)-3-methyl-8-(pyridin-3-yl)-lH-imidazo[4,5-
c]quinolin-2(3H)-one,
2-(5-(8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-(cyanomethyl)-2-oxo-2,3-
dihydro-lH-imidazo[4,5-c]quinolin-l-yl)pyridin-2-yl)-2-methylpropanenitrile,
2-(5-(3-(Cyanomethyl)-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)pyridin-2-yl)-2-methylpropanenitrile,
2-(5-(3-Allyl-2-oxo-8-(pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-lyl)
pyridin-2-yl)-2-methylpropanenitrile,
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-l-(6-methoxypyridin-3-yl)-3-methyl-
1H-imidazo [4,5-c]quinolin-2(3H)-one,
1-(6-Methoxypyridin-3-yl)-3-methyl-8-(quinolin-3-yl)-lH-imidazo[4,5-c]quinolin-
2(3H)-one,
2-(l-(6-Methoxypyridin-3-yl)-2-oxo-8-(pyridin-3-yl)-lH-imidazo[4,5-c]quinolin-
3(2H)-yl)acetonitrile,
l-(6-Methoxypyridin-3-yl)-3-methyl-8-(5-(trifluoromethyl) pyridin-3-yl)-lHimidazo[
4,5-c] quinolin-2(3H)-one,
1-(6-Methoxypyridin-3-yl)-3-methyl-8-(pyridin-3-yl)-lH-imidazo[4,5-c] quinolin-
2(3H)-one,
2-(l-(6-Methoxypyridin-3-yl)-2-oxo-8-(quinolin-3-yl)-lH-imidazo[4,5-c]quinolin-
3(2H)-yl) acetonitrile,
8-(6-(Dimethylamino)pyridin-3-yl)- 1-(6-methoxypyridin-3-yl)-3-methyl- 1Himidazo[
4,5-c] quinolin-2(3H)-one,
l-(6-Methoxypyridin-3-yl)-3-methyl-8-(6-(methylamino)-5-(trifluoromethyl)pyridin-
3-yl)-lH-imidazo[4,5-c] quinolin-2(3H)-one,
8-(2-Fluoro-5-(trifluoromethyl)phenyl)-l-(6-methoxypyridin-3-yl)-3-methyl-lHimidazo[
4,5-c] quinolin-2(3H)-one,
l-(6-Methoxypyridin-3-yl)-3-methyl-8-(pyridin-4-yl)-lH-imidazo[4,5-c] quinolin-
2(3H)-one,
8-(5-Fluoro-2-methoxyphenyl)-l-(6-methoxypyridin-3-yl)-3-methyl-lH-imidazo[4,5-
c]quinolin-2(3H)-one,
8-(6-Amino-5-(trifluoromethyl) pyridin-3-yl)-l-(6-ethoxypyridin-3-yl)-3-methyl-lHimidazo[
4,5-c]quinolin-2(3H)-one,
8-(6-(Dimethylamino) pyridin-3-yl)-l-(6-ethoxypyridin-3-yl)-3-methyl-lH-imidazo
[4,5-c]quinolin-2(3H)-one,
l-(6-Ethoxypyridin-3-yl)-3-methyl-8-(quinolin-3-yl)-lH-imidazo[4,5-c]quinolin-
2(3H)-one,
8-(2,6-Difluoropyridin-3-yl)-l-(6-ethoxypyridin-3-yl)-3-methyl-lH-imidazo[4,5-
c]quinolin-2(3H)-one,
l-(6-Ethoxypyridin-3-yl)-8-(2-methoxypyrimidin-5-yl)-3-methyl-lH-imidazo[4,5-
c]quinolin-2(3H)-one,
1-(6-Ethoxypyridin-3-yl)-3-methyl-8-(quinolin-6-yl)-lH-imidazo[4,5-c]quinolin-
2(3H)-one,
2-(l-(6-Methoxy-2-methylpyridin-3-yl)-2-oxo-8-(quinolin-3-yl)-lH-imidazo[4,5-
c]quinolin-3 (2H)-yl) acetonitrile,
2-(l-(6-Methoxy-2-methylpyridin-3-yl)-2-oxo-8-(6-(trifluoromethyl)pyridin-3-yl)-
lH-imidazo[4,5-c]quinolin-3(2H)-yl) acetonitrile,
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-l-(6-methoxy-2-methylpyridin-3-yl)-3-
methyl-lH-imidazo[4,5-c]quinolin-2(3H)-one,
l-(6-Methoxy-2-methylpyridin-3-yl)-3-methyl-8-(5-(trifluoromethyl)pyridin-3-yl)-
1H-imidazo [4,5-c]quinolin-2(3H)-one,
8-(6-(Dimethylamino) pyridin-3-yl)- 1-(6-methoxy-2-methylpyridin-3-yl)-3-methyl-
1H-imidazo [4,5-c] quinolin-2(3H)-one,
l-(6-Methoxy-2-methylpyridin-3-yl)-3-methyl-8-(quinolin-3-yl)-lH-imidazo[4,5-
c]quinolin-2(3H)-one,
5-(3-(Cyanomethyl)-2-oxo-8-(pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c] quinolin-
1-yl)picolinonitrile,
5-(3-(l-Cyanoethyl)-2-oxo-8-(pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-
1-yl)picolinonitrile,
5-(3-Methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-l-yl)
picolinonitrile,
5-(8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lHimidazo[
4,5-c]quinolin-l-yl)picolinonitrile,
5-(8-(2-Fluoropyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-
1-yl) picolinonitrile,
5-(8-(6-Fluoropyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-
1-yl) picolinonitrile,
5-(8-(6-Methoxypyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)picolinonitrile,
5-(3-Methyl-2-oxo-8-(pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-l-yl)
picolinonitrile,
5-(8-(6-(Dimethylamino)pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)picolinonitrile,
5-(3-(Cyanomethyl)-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-
1-yl)picolinonitrile,
5-(3-(l-Cyanoethyl)-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-
1-yl)picolinonitrile,
3-Methyl-8-(pyridin-3-yl)-l-(6-(trifluoromethyl)pyridin-3-yl)-lH-imidazo[4,5-
c]quinolin-2(3H)-one,
3-Methyl-8-(quinolin-3-yl)- 1-(6-(trifluoromethyl)pyridin-3-yl)- lH-imidazo[4,5-
c]quinolin-2(3H)-one,
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-methyl-l-(6-(nifluoromethyl)pyridin-
3-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-one,
3-Methyl-l,8-bis(6-(trifluoromethyl)pyridin-3-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-
one,
8-(2,6-Difluoropyridin-3-yl)-3-methyl-l-(6-(trifluoromethyl)pyridin-3-yl)-lHimidazo[
4,5-c]quinolin-2(3H)-one,
6-Chloro-5-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-
c]quinolin- 1-yl)picolinonitrile,
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-l-(2-chloro-6-(trifluoromethyl) pyridin-
3-yl)-3 -methyl- 1H-imidazo [4,5 -c]quinolin-2(3H)-one,
l-(6-Chloropyridin-3-yl)-3-methyl-8-(pyridin-3-yl)-lH-imidazo[4,5-c]quinolin-
2(3H)-one,
l-(6-Chloropyridin-3-yl)-3-methyl-8-(quinolin-3-yl)-lH-imidazo[4,5-c]quinolin-
2(3H)-one,
l -(2,6-Dichloropyridin-3-yl)-3-methyl-8-(pyridin-3-yl)- lH-imidazo[4,5-c]quinol
2(3H)-one,
l-(6-Chloro-2-(trifluoromethyl)pyridin-3-yl)-3-methyl-8-(pyridin-3-yl)-lHimidazo[
4,5-c]quinolin-2(3H)-one,
l-(6-(Dimethylamino)pyridin-3-yl)-3-methyl-8-(quinolin-3-yl)-lH-imidazo[4,5-
c]quinolin-2(3H)-one,
3-Methyl-8-(quinolin-3-yl)-l-(quinolin-6-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-one,
3-Methyl- 1-(quinolin-6-yl)-8-(5-(trifluoromethyl)pyridin-3-yl)- lH-imidazo[4,5-
c]quinolin-2(3H)-one,
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-methyl-l-(quinolin-6-yl)-lHimidazo[
4,5-c]quinolin-2(3H)-one,
3-Methyl- l-(2-morpholinoethyl)-8-(pyridin-3-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-
one,
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-methyl-l-(2-morpholinoethyl)-lHimidazo[
4,5-c]quinolin-2(3H)-one,
3-Methyl- l-(2-morpholinoethyl)-8-(quinolin-3-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-
one,
3-Methyl- 1-(6-(4-methylpiperazin- 1-yl)pyridin-3-yl)-8-(pyridin-3-yl)- 1Himidazo[
4,5-c]quinolin-2(3H)-one,
l-(6-Chloro-2,4'-bipyridin-3-yl)-3-methyl-8-(pyridin-3-yl)-lH-imidazo[4,5-
c]quinolin-2(3H)-one,
3-Methyl- l-(6-mo^holinopyridin-3-yl)-8-(quinolin-3-yl)-lH-imidazo[4,5-c]quinolin-
2(3H)-one,
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-3-methyl-l-(2-(trifluoromethyl)
pyrimidin-5-yl)-lH-imidazo[4,5-c]quinolin-2(3H)-one, or
8-(5-Amino-6-methoxypyridin-3-yl)- 1-(6-methoxypyridin-3-yl)-3-methyl- 1Himidazo[
4,5-c]quinolin-2(3H)-one;
or a pharmaceutically acceptable salt, a stereoisomer, a tautomer or N-oxide thereof.
The compound according to claim 15, selected from:
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-l-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-
3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-5-ium methanesulfonate,
8-(6-Amino-5-(trifluoromethyl)pyridin-3-yl)-l-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-
3-methyl-2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-5-ium chloride,
8-(Isoquinolin-4-yl)- l-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-3-methyl-2-oxo-2,3-
dihydro-lH-imidazo[4,5-c]quinolin-5-ium methanesulfonate,
8-(Isoquinolin-4-yl)- l-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-3-methyl-2-oxo-2,3-
dihydro-lH-imidazo[4,5-c]quinolin-5-ium chloride,
8-(6-Ammonio-5-(trifluoromethyl)pyridin-3-yl)-l-(6-methoxypyridin-3-yl)-3-methyl-
2-oxo-2,3-dihydro-lH-imidazo[4,5-c]quinolin-5-ium methanesulfonate, and
8-(6-Ammonio-5-(trifluoromethyl)pyridin-3-yl)-3-methyl-2-oxo-l-(6-
(trifluoromethyl)pyridin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-5-ium
methanesulfonate,
or a stereoisomer, a tautomer or N-oxide thereof.
17. A pharmaceutical composition comprising a therapeutically effective amount of a
compound of formula (I) as defined in any one of the claims 1 to 16 or a
pharmaceutically acceptable salt and a pharmaceutically acceptable excipient or a
carrier.
18. Use of a compound of formula (I) as defined in any one of the claims 1 to 16 or a
pharmaceutically acceptable salt thereof for the treatment of a disease or disorder
mediated by one or more kinases selected from phosphatidylinositol 3 kinase (PI3K),
mammalian target of rapamycin (mTOR), activin receptor-like kinase 1 (ALK1) or
activin receptor-like kinase 2 (ALK2).
19. The use according to claim 18, wherein the disease is a proliferative disease.
20. The use according to claim 19, wherein the proliferative disease is cancer.
21. The use according to claim 20, wherein the cancer is selected from: leukemia, lung
cancer, brain tumors, Hodgkin's disease, liver cancer, kidney cancer, bladder cancer,
breast cancer, endometrial cancer, head and neck cancer, lymphoma, melanoma,
cervical cancer, thyroid cancer, gastric cancer, germ cell tumor, cholangiocarcinoma,
extracranial cancer, sarcoma, mesothelioma, malignant fibrous histiocytoma of bone,
retinoblastoma, esophageal cancer, multiple myeloma, oral cancer, pancreatic cancer,
neuroblastoma, skin cancer, ovarian cancer, recurrent ovarian cancer, prostate cancer,
testicular cancer, colorectal cancer, lymphoproliferative disease, refractory multiple
myeloma, cancer of urinary tract, resistant multiple myeloma or myeloproliferative
disorder.
Use of a compound of formula (I) as defined in any one of the claims 1 to 16 or a
pharmaceutically acceptable salt thereof for the treatment of a disease mediated by
tumor necrosis factor-a (TNF- a) or interleukin-6 (IL-6).
The use according to claims 18 or 22, wherein the disease is an inflammatory disease.
The use according to claim 23, wherein the inflammatory disease is selected from:
rheumatoid arthritis, Crohn's disease, ulcerative colitis, inflammatory bowel disease,
chronic non-rheumatoid arthritis, osteoporosis, septic shock, psoriasis or
atherosclerosis.
Use of a compound of formula (I) as defined in any one of the claims 1 to 16 or a
pharmaceutically acceptable salt thereof for the treatment of a disease mediated by
vascular endothelial growth factor (VEGF).
The use according to claims 18 or 25, wherein the disease is angiogenesis related
disorder.
The use according to claim 26, wherein the disease is: (i) an inflammatory disorder
selected from immune and non-immune inflammation, chronic articular rheumatism,
psoriasis, diabetic retinopathy, neovascular glaucoma, capillary proliferation in
atherosclerotic plaques or osteoporosis; or (ii) cancer associated disorder selected
from solid tumor, solid tumor metastases, angiofibroma, retrolental fibroplasia,
hemangioma or Kaposi's sarcoma.
28. Use of a compound of formula (I) as defined in any one of the claims 1 to 16 or a
stereoisomer, a tautomer, an N-oxide, a pharmaceutically acceptable salt or a solvate
thereof for the treatment of proliferative disease, inflammatory disease or an
angiogenesis related disorder.
29. A process for the preparation of a compound of formula (I),
wherein Ri, R2 and R 3 are as defined for formula (I) in claim 1,
comprising:
a) reacting a compound of formula (6);
(6)
wherein, R is as defined for formula (I) in claim 1,
with a reagent such as trichloromethylchloroformate or triphosgene in the presence of
a base selected from triethylamine or trimethylamine in a solvent selected from
dichloromethane or chloroform to obtain a compound of formula (7);
b) reacting the compound of formula (7), with a compound of formula R2-hal,
wherein, hal is halogen and R2 is as defined for formula (I) in claim 1, in the presence
of sodium hydride as a base, to obtain a compound of formula (8)
(8)
wherein R and R2are as defined for formula (I) in claim 1;
(c) reacting the compound of formula (8) with a compound of formula R -B(OH)2
wherein, R is as defined for formula (I) in claim 1, in the presence of palladium
dichlorobistriphenylphosphine as a coupling agent, to obtain the compound of
formula (I),
wherein Ri, R2 and R3 are as defined for formula (I);
d) optionally converting the resulting compound of formula (I) into
pharmaceutically acceptable salt.